COVID-19 Mitigation Products

(PPE, Serologic Test, Contact Tracing System, COVID-19 Drugs, COVID-19 Vaccine, Polymerase Chain Reaction, PCR Test Kits, Blockchain Technologies, Surge Hospitals, Self-collection Swabs, AI, Personal Protection Gear, Teleradiology, Eye Protection, Ultrasound, Dialysis, CT, X-Ray, Medical Glass, Telemedicine, Face Shields, Gowns, Homecare, Gloves, E-Health, Robotic PCR, Antigen Test, Monoclonal Antibody, Face Masks, Therapeutic Drugs, ICU, PACS, Contact Tracing, PPE Sterilization and More)

Market Research, to 2024



Homeland Security Research Corp.

COVID-19 Mitigation Products

(PPE, Serologic Test, Contact Tracing System, COVID-19 Drugs, COVID-19 Vaccine, Polymerase Chain Reaction, PCR Test Kits, Blockchain Technologies, Surge Hospitals, Self-collection Swabs, AI, Personal Protection Gear, Teleradiology, Eye Protection, Ultrasound, Dialysis, CT, X-Ray, Medical Glass, Telemedicine, Face Shields, Gowns, Homecare, Gloves, E-Health, Robotic PCR, Antigen Test, Monoclonal Antibody, Face Masks, Therapeutic Drugs, ICU, PACS, Contact Tracing, PPE Sterilization and More)

Market Research, to 2024

Vol.1

Homeland Security Research Corp. (HSRC) is an international market and technology research firm specializing in the Public Safety Industry. HSRC provides premium market off-the-shelf and custom reports on present and emerging technologies and industry expertise, enabling global clients to gain time-critical insight into business opportunities. HSRC's clients include the EU, NATO, U.S. Congress, DHS, U.S. Army, U.S. Navy, DOD, DOT, and US Congress GAO among others; as well as Counter Terror & Public Safety agencies in Japan, Korea, Taiwan, Israel, Canada, UK, Germany, Australia, Sweden, Finland, Singapore. With over 1050 private sector clients (75% repeat customers), including major defense and public safety vendors, and Fortune 2000 companies, HSRC earned the reputation as the industry's Gold Standard for COVID-19 Pandemic Mitigation market reports.

Washington D.C. 20004, 601 Pennsylvania Ave., NW Suite 900, Tel: 202-455-0966, info@hsrc.biz, www.homelandsecurityresearch.com

Acknowledgements

The authors of this report wish to convey their sincere thanks to all the COVID-19 researchers.

government officials, pandemic experts, healthcare planners, engineers, scientists, vendors, and COVID-19 healthcare professionals who granted us interviews, provided published and non-published presentations & papers - giving us an invaluable insight into the working of the COVID-19 mitigation community and industry. The list below contains the names of some of the people, companies and events' organizers that have helped us directly or indirectly in the preparation of this report. We thank them and many others.

Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases. Tedros Α. Ghebreyesus, Director-General, World Organization (WHO), Yazdan Yazdanpanah Chairperson GLOPID-R, Linda Degutis, Emory University Rollins School of Public Health and Lecturer, Yale School of Medicine, Craig Fugate - former administrator of FEMA and former director of the Florida Emergency Management Division, Ateev Mehrotra, Harvard Medical School, , Kent Smetters, Leonard Davis Institute of Health Economics Senior Fellow, Wharton School Boettner Faculty Director, Penn Wharton Budget Model, Wharton school, Margaret "Peggy" Hamburg, National Academy of Medicine, and former FDA Commissioner, John-Martin Lowe, Assistant Vice Chancellor for Interprofessional Health Security Training and Education and Associate Professor of Environmental, Agricultural, Occupational Health, University of Nebraska Medical Center, Arturo Casadevall, Chair, Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Steve Fuller, Warwick University; Jennifer Kavanagh, RAND Corporation; **Tehilla Shwartz Altshuler**, Democracy Institute; Ofer Friedman, King's College London; Tomer Shadmi, Tel Aviv University; Attila Somfalvi, INSS, Ayelet Bar'Am Tsabari, Technion Israel Institute of Technology; Jacob Moran-Gilad, Ben Gurion University; Sir Lawrence Freedman, King's College London; Sonoo Thadaney Israni Stanford University; Andrew Auerbach, University of California, San Francisco; Andrew Beam, Harvard University; Paul Bleicher, Optumlabs; Wendy Chapman, University of Melbourne; Jonathan Chen, Stanford University; Guilherme Del Fiol, University of Utah; Hossein Estiri, Harvard Medical School; James Fackler, Johns Hopkins School of Medicine; Stephan Fihn, University of Washington; Anna Goldenberg, University of Toronto; Seth Hain, Epic; Jaimee Heffner, Fred Hutchinson Cancer Research Center; Edmund Jackson, Hospital Corporation of America: Jeffrey Klann, Harvard Medical School and Massachusetts General Hospital; Rita Kukafka, Columbia University; Hongfang Liu, Mayo Clinic; Douglas Mcnair, Bill & Melinda Gates Foundation; Eneida Mendonça, Regenstrief Institute; Joni Pierce, University of Utah; W. Nicholson Price II,

University of Michigan; Joachim Roski, Booz Allen Hamilton; Suchi Saria, Johns Hopkins University; Nigam Shah, Stanford University; Ranak Trivedi, Stanford University; Jenna Wiens, University of Michigan; **Thomas M.** Connelly, Jr., Chair, American Chemical Society, Washington, DC; Steven M. Bellovin, Columbia University, New York, New York; Patrick M. Boyle, Ginkgo Bioworks Inc., Boston, Massachusetts: Katherine Charlet, Carnegie Endowment For International Peace, Washington, DC; J. Bradley Dickerson, Sandia National Laboratories, Albuquerque, New Mexico; Diane Dieuliis, National Defense University, Washington, DC; Gerald Epstein, National Defense University, Washington, DC; Steven L. Evans, Dow Agro Science (Retired), Indianapolis, Indiana; George B. Frisvold, University of Arizona, Tucson; Jeffrey L. Furman, Boston University Linda Kahl, Sciscript Communications, Walnut Creek, California Isaac S. Kohane, Harvard Medical SchoolKelvin H. Lee, University of Delaware, Mary E. Maxon, Lawrence Berkeley National Laboratory Maureen Mccann, Purdue University, West Lafayette, Piers D. Millett, Igem, Boston, Massachusetts; Mathew Golden, University of Washington, School of Public Health; Trevor Bedford, Fred Hutchinson Cancer Research Center; Michael Wells, Broad Institute; Lisa Hirschhorn, Northwestern University; Nevan Krogan, University of California, San Francisco: Joe DeRisi. Chan Zuckerberg-BioHub, University of California, San Francisco: Rebecca Cunningham, University of Michigan: Clyde Brown, Florida A&M University; Emily Landon, University of Chicago; Tyrone Grandison, Data-Driven institute; Shobita Parthasarathy, University of Michigan; Greg Millett, amfAR, the Foundation for AIDS Research; Pardis Sabeti, Harvard University (Invited); Beth Noveck, the Governance Lab; Gerard Clancy, University of Tulsa; Ashish K. Jha, Director, Harvard Global Health Institute; K.T. Li, Global Health, Harvard T.H. Chan School of Public Health; **Thomas Tsai**, Department of Health Policy and Management, Harvard T.H. Chan School of Public Health; Jose Figueroa, Health Policy and Management, Harvard T.H. Chan School of Public Health: **Annie Linskey**. Washington Post: Josh Dawsey, Washington Post: Isaac Stanley-Becker, Washington Post: Chelsea Janes, Washington Post; Karl Schmedders, International Institute for Management Development Jung Park, International Institute for Management Development Robert Earle, University of Zürich; Harvey V. Fineberg, Gordon and Betty Moore Foundation; Kristian G. andersen, The Scripps Research Institute: Mary T. Bassett, Harvard T.H. Chan School of Public Health: Trevor Bedford, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center; Georges C. Benjamin, Executive Director, American Public Health Association: Richard E. Besser, President and Chief Executive officer, Robert Wood Johnson Foundation; Peter Daszak, President, Ecohealth Alliance: Ellen P. Embrey, Managing Partner, Stratitia Inc.; Diane E. Griffin, Johns Hopkins Bloomberg School of Public Health; Margaret A. Hamburg, National Academy of Medicine; John L. Hick, Hennepin Healthcare and Professor of Emergency Medicine, University of Minnesota; Kent E. Kester, Vice President and Head. Translational Science and Biomarkers, Sanofi Pasteur; Patricia A. King, Georgetown University Law Center; Jonna A. Mazet, Professor of

Epidemiology and Disease Ecology, University of California, Davis, School of Veterinary Medicine; Phyllis D. Meadows, Senior Fellow, The Kresge Foundation; Tara O'toole, Executive Vice President, In-Q-Tel; Alexandra Phelan, Center For Global Health Science and Security, Department of Microbiology and Immunology, Georgetown University; David A. Relman, Stanford University; Mark S. Smolinski, President, Ending Pandemics; David R. Walt, Harvard Medical School; Donald Berwick, Institute For Healthcare Improvement; Carlos Del Rio, Emory Vaccine Center; Baruch Fischhoff, Carnegie Mellon University; Dan Hanfling, In-Q-Tel; James Hodge, Arizona State University: Sundaresan Jayaraman, Georgia Tech; Michael Osterholm, University of Minnesota; Ed Nardel, Harvard University; Jennifer Nuzzo, Johns Hopkins Bloomberg School of Public Health; Richard Serino, Harvard T.H. Chan School of Public Health; Beth Weaver, Resolve; Matthew Wynia, University of Colorado Center For Bioethics and Humanities; Dr. Andrea Ammon, Director of the European Centre for Disease Prevention and Control (ECDC).

VENDORS

Thermo Fisher Scientific, Abbott Laboratories, Agilent Technologies GE Healthcare, Gibco, Invitrogen, Ion Torrent, Kapa Biosystems, Maxim Biotech, Roche, Sigma-Aldrich Corp. Siemens Healthineers, Philips Healthcare, Toshiba, Google, Fujifilm Holdings Corporation, Agfa Healthcare, Allscripts Healthcare Solutions, McKesson Corporation, Dell Technologies Inc., IBM Corporation, Koninklijke Philips NV, Lexmark International Inc., Novarad Corporation, Delta Plus Group, Pyramex Safety, Essilor of America, Ironwear, 3M Company, Bullard, Encon Safety Products, MCR Safety, ERB Industries Inc., Ergodyne, Gateway Safety, Inc., Gentex Corporation, VisionAid, Inc., Safety Optical Service, Honeywell Safety Products, Sellstrom Manufacturing Company (SureWerx), Kimberly-Clark Professional, HexArmor, Radians Inc., Bollé Safety, Frequency Therapeutics, Inc., Gilead Sciences, Inovio Pharmaceuticals, Abbott Diagnostics, AbCellera, Agilent Technologies Inc., BlueDot, Dupont, Eli Lilly, Johnson & Johnson (Janssen), Merck, Metabiota, Moderna, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi, Vir Biotechnology, Inc., WuXi Biologics, Ford, General Motors, Sensory, Inc., Skymind, Inc., Xilinx, Inc., Google LLC, Intel Corporation, Micron Technology, Inc. Microsoft Corporation, Nvidia Corporation, Amazon Web Services Inc., Qualcomm Incorporated, Samsung Electronics Co., Ltd.

We thank organizers, speakers & participants of the following conferences and webinars:

AAAS Annual Meeting Seattle, Washington, 13-16 February 2020; EHA series of webinars, weekly from April 1, 2020; Challenges Facing the COVID-19 Pandemic - Webinar hosted by MECIDS, CORDS, Ending Pandemics, Tel Aviv University School of Public Health and University of San Francisco. April 2, 2020; ICAO COVID-19 Webinar

Series, from April 30, 2020; European Centre for Disease Prevention and Control: Chinese respiratory doctors share COVID-19 experience with overseas medics, March 19, 2020; ISUOG webinar series on COVID-19, from March 17, 2020; CEPR: The Political Economy of COVID-19 — what do we learn from Emerging Europe? May 28, 2020; International Federation of Consulting Engineers COVID-19 Webinar Series, from April 7, 2020; How to ventilate COVID-19 patients, ESICM Webinar, April 2, 2020; INSEAD COVID-19 Webinar Series, from May 28, 2020; COVID-19 and lung health, "The Union" Webinar Series, from April 30, 2020; IATI COVID-19 Innovation Conference, April 6-7, 2020.

Table of Contents

1	Market Definition	9
	1.1 Introduction	9
	1.2 Scenario A: Assumptions	9
	1.3 Scenario B: Assumptions	9
2	Executive Summary	11
	2.1 Key Findings	11
	2.2 COVID-19 Mitigation Funding (January - May 2020)	27
	2.3 Key Conclusions	30
	2.4 COVID-19 Pandemic Mitigation Products Market Research	
	Vectors	
	2.5 COVID-19 Pandemic Mitigation R&D Challenges	
	2.6 Global COVID-19 Pandemic Mitigation Market - 2020-2024	
	2.6.1 Products & Services Groups Markets	
	2.6.2 Products & Services Markets	
	2.6.3 End User Markets	
	2.6.5 Regional Markets	
3	The SARS-CoV-2 2019 Pandemic	
	3.1 COVID-19 Basics	
	3.2 COVID-19 Infection Rate	
	3.3 Social Distancing	
	3.5 Comparison of SARS-CoV-2 and Common Cold and Flu	04
	Viruses	65
	3.6 The SARS-CoV-2 Genome Information	
	3.7 Active Infection Testing	
	3.7.1 Nucleic Acid Detection	
	3.7.2 Antigen Detection	
	3.7.3 Other Technologies	69
	3.8 Serology Testing	70
4	Market Drivers	73
5	Market Inhibitors	7/
6	COVID-19 Pandemic Mitigation Products Market SWOT Analysis	75
	6.1 Strengths	
	6.2 Weaknesses	
	6.3 Opportunities	
	6.4 Threats	
7	Business Opportunities & Challenges	
8	COVID-19 Pandemic Mitigation Industry	83

	8.1 8.2	COVIE	OVID-19 Pandemic Mitigation Products Value Chain D-19 Pandemic Mitigation Products Industry Primary	
			es	84
	8.3		D-19 Pandemic Mitigation Products industry Support ies	84
9	to Er	ntry, Su	andemic Mitigation Products Industry: Barriers pplier Power, Buyer Power & Barriers to	86
GL	OBAL	MARKE	Т	87
10			D-19 Pandemic Mitigation Market - 2020-2024	07
	10.1		COVID-19 Pandemic Mitigation Products & Services SMarkets – 2020-2024	07
	10	.1.1	Global COVID-19 Pandemic Mitigation Products &	07
	10	. 1 . 1	Services Groups Markets: Scenario A	87
	1	0.1.1.1		
		0.1.1.2		
		0.1.1.2		
		.1.2	Global COVID-19 Pandemic Mitigation Products &	00
	10	. 1 . 2	Services Groups Markets: Scenario B	90
	1	0.1.2.1		
		0.1.2.2		
		0.1.2.3		
			Global COVID-19 Pandemic Mitigation Market:	
	10		Scenarios Comparison	92
	10.2	Global	COVID-19 Pandemic Mitigation Products & Services	
			ts – 2020-2024	93
	10	.2.1	Global COVID-19 Pandemic Mitigation Products &	
	. 0		Services Markets: Scenario A	94
	1	0.2.1.1		
			Market Dynamics	
		.2.2	Global COVID-19 Pandemic Mitigation Products &	
			Services Markets: Scenario B	98
	1	0.2.2.1	Market Size	
		0.2.2.2	Market Dynamics	
		.2.3	Global COVID-19 Pandemic Mitigation Products &	
			Services Groups Markets: Scenarios Comparison	103
	10.3	Global	End User COVID-19 Pandemic Mitigation Markets –	
			2024	104
	10	.3.1	Global COVID-19 Pandemic Mitigation End User	
			Markets: Scenario A	104
	1	0.3.1.1	Market Size	
	1	0.3.1.2		
	1	0.3.1.3	Market Share	

10.3.2	Global COVID-19 Pandemic Mitigation End User	
	Markets: Scenario B	106
10.3.2.	1 Market Size	106
10.3.2.2	2 Market Dynamics	106
10.3.2.3	3 Market Share	
10.3.3	Global COVID-19 Pandemic Mitigation End User	
	Markets: Scenarios Comparison	107
10.4 Glob	al COVID-19 Pandemic Mitigation Products & Services	
	tet by Revenue Source – 2020-2024	108
10.4.1	Global COVID-19 Pandemic Mitigation Products &	
	Services Market: Scenario A	108
10.4.2	Global COVID-19 Pandemic Mitigation Products &	
	Services Market: Scenario B	109
10.4.3	Global COVID-19 Pandemic Mitigation Revenue	
	Sources: Scenarios Comparison	111
10.5 Regi	onal COVID-19 Pandemic Mitigation Markets – 2020-	
	ļ	112
10.5.1	Regional COVID-19 Pandemic Mitigation Market:	
	Scenario A	112
10.5.1.	1 Market Size	112
10.5.1.2	2 Market Dynamics	112
10.5.1.3		
10.5.2	Regional COVID-19 Pandemic Mitigation Market:	
	Scenario B	113
10.5.2.		
10.5.2.2	2 Market Dynamics	114
10.5.2.3		
10.5.3	Regional COVID-19 Pandemic Mitigation Market:	
	Scenarios Comparison	115
10.6 Natio	onal COVID-19 Pandemic Mitigation Markets – 2020-	
	ļ	116
10.6.1	National COVID-19 Pandemic Mitigation Market:	
	Scenario A	116
10.6.1.	1 Market Size	116
10.6.1.2	2 Market Dynamics	118
10.6.1.3		
10.6.2	National COVID-19 Pandemic Mitigation Market:	
	Scenario B	119
10.6.2.		
10.6.2.2		
10.6.2.3		
	COVID-19 National Markets: Scenarios Comparison	

List of Tables

Table 1 - COVID-19 June 1, 2020 COVID-19 Cases and the Number Dead	
per Million by Country	26
Table 2 - Global Products & Services Groups Markets' Size [\$M]: Scenario A - 2020-2024	46
Table 3 - Global Products & Services Groups Markets' Size [\$M]: Scenario	
B - 2020-2024	47
Table 4 - Global Products & Services Markets' Size [\$M]: Scenario A - 2020-2024	50
Table 5 - Global Products & Services Markets' Size [\$M]: Scenario B -	00
2020-2024	52
Table 6 - Global End User Markets' Size [\$M]: Scenario A - 2020-2024	
Table 7 - Global End User Markets' Size [\$M]: Scenario B - 2020-2024	54
Table 8 - Global Market Size by Revenue Source [\$M] Scenario A - 2020-	0 .
2024	55
Table 9 - Global Market Size by Revenue Source [\$M] Scenario B - 2020-	00
2024	55
Table 10 - Regional Markets Size [\$M]: Scenario A - 2020-2024	
Table 11 - Regional Markets Size [\$M]: Scenario B - 2020-2024	
Table 12 - National Markets Size [\$M]: Scenario A - 2020-2024	
	57
Table 14 - COVID-19 Pandemic Mitigation Products Market: Business	0 .
Opportunities	81
Table 15 - Global Products & Services Groups Markets' Size [\$M]:	0 .
Scenario A - 2020-2024	87
Table 16 - Global Products & Services Groups Markets' Dynamics [%]:	0 .
Scenario A - 2020-2024	89
Table 17 - Global Products & Services Groups Markets' Size [\$M]:	00
Scenario B - 2020-2024	90
Table 18 - Global Products & Services Groups Markets' Dynamics [%]:	00
Scenario B - 2020-2024	91
Table 19 - Global Products & Services Markets' Size [\$M]: Scenario A -	• .
2020-2024	94
Table 20 - Global Products & Services Markets' Dynamics [%]: Scenario A	0 .
- 2020-2024	. 96
Table 21 - Global Products & Services Markets' Size [\$M]: Scenario B -	0 0
2020-2024	98
Table 22 - Global Products & Services Markets' Dynamics [%]: Scenario B	00
- 2020-2024	101
Table 23 - Global End User Markets' Size [\$M]: Scenario A - 2020-2024	
Table 24 - Global End User Markets' Dynamics [%]: Scenario A - 2020-	
2024	.105
Table 25 - Global End User Markets' Size [\$M]: Scenario B - 2020-2024	
Table 26 - Global End User Markets' Dynamics [%]: Scenario B - 2020-	
2024	.106

Table 27 - Global Market Size by Revenue Source [\$M] Scenario A - 2020- 2024	108
Table 28 - Global Markets Dynamics by Revenue Source [%]: Scenario A - 2020-2024	108
Table 29 - Global Market Size by Revenue Source [\$M] Scenario B - 2020- 2024	109
Table 30 - Global Markets Dynamics by Revenue Source [%]: Scenario B - 2020-2024	110
Table 31 - Regional Markets Size [\$M]: Scenario A - 2020-2024 Table 32 - Regional Markets Dynamics by Region [%]: Scenario A - 2020-	112
2024	112
Table 33 - Regional Markets Size [\$M]: Scenario B - 2020-2024	
Table 34 - Regional Markets Dynamics [%]: Scenario B - 2020-2024	
Table 35 - National Markets Size [\$M]: Scenario A - 2020-2024	116
Table 36 - National Markets Dynamics [%]: Scenario A - 2020-2024	118
Table 37 - National Markets Size [\$M]: Scenario B - 2020-2024	119
Table 38 - National Markets Dynamics [%]: Scenario B - 2020-2024	121

List of Figures

Figure 1 - Mortality Rate Comparison, MERS, SARS & COVID-19	11
Figure 2 - COVID-19 Vs. Other Pandemics: Ro & Fatality Rate	13
Figure 3 - The Effect of the PRC Draconic Social Distancing Policy	
Figure 4 - Healthcare Expenditure [\$B] by County - 2019	
Figure 5 - Lower and Delay the Pandemic Peak Strategy	
Figure 6 - The 10 Countries with the Most Foreign Drug Establishments	
Shipping to the United States as of 2019, by Country	21
Figure 7 - Number of (2019) Intensive Care Beds [000] by Country	22
Figure 8 - ICU Beds (2019) Per 100,000 Inhabitants, by Country	
Figure 9 - The WHO Research Funding (\$8.5 Billion) Allocation	
Figure 10 - A Serologic Test Kit	
Figure 11 - Modeling COVID-19 Pandemic: 'Uncertainty is the Only Certainty'	
Figure 12 - The Way an Application Detects a Person w/o Symptoms	
Figure 13 - Countries Enacting Contact Tracing Services to Mitigate the	00
COVID-19 Pandemic	39
Figure 14 - COVID-19 Pandemic Impact on Global Economics &	00
Geopolitics	41
Figure 15 - Global COVID-19 Pandemic Mitigation Products Market	
Vectors	45
Figure 16 - Global Products & Services Groups Markets' Size [\$M]:	
Scenario A - 2020-2024	47
Figure 17 - Global Products & Services Groups Markets' Size [\$M]:	
Scenario B - 2020-2024	48
Figure 18 - Global Products & Services Markets' Size [\$M]: Scenarios A	
and B - 2020-2024	49
Figure 19 - The SARS-CoV-2 Virus	
Figure 20 – Epidemics & Pandemics Historical Timeline	
Figure 21 - COVID-19 Ro & Fatality Rate Vs. Other Pandemics Ro &	
Fatality Rate	62
Figure 22 - How Herd Immunity Can Stop the COVID-19	
Figure 23 - The Effect of an Pandemic Early Stage Using "Social	
	63
Figure 24 - The SARS-CoV-2, Size, Content, Genome and Replication	
Timescales	64
Figure 25 - Serology Test Process	
Figure 26: COVID-19 Pandemic Mitigation Products Industry Value Chain	83
Figure 27 - COVID-19 Pandemic Mitigation Products Security Systems	00
Market Competitive Analysis	86
Figure 28 - Global Products & Services Groups Markets' Size [\$M]:	00
Scenario A - 2020-2024	88
Figure 29 - Global Products & Services Groups Market Shares [%]:	50
Scenario A - 2020-2024	89

Figure 30 - Global Products & Services Groups Markets' Size [\$M]: Scenario B - 2020-2024	91
Figure 31 - Global Products & Services Groups Market Shares [%]:	91
Scenario B - 2020-2024	92
Figure 32 - Global COVID-19 Mitigation Market Size [\$M]: Scenarios A and	
B - 2020-2024	92
Figure 33 - Global Products & Services Markets' Size [\$M]: Scenarios A	
and B - 2020-2024	103
Figure 34 - Global End User Markets' Shares [%]: Scenario A - 2020-2024	
Figure 35 - Global End User Markets' Shares [%]: Scenario B - 2020-2024	107
Figure 36 - Global End User Markets' Size [\$M]: Scenarios A and B - 2020-	
2024	107
Figure 37 - Global Market Shares by Revenue Source [%]: Scenario A -	
2020-2024	109
Figure 38 - Global Market Shares by Revenue Source [%]: Scenario B -	
	110
Figure 39 - Global Revenue Sources [\$M]: Scenarios A and B - 2020-2024	
Figure 40 - Regional Market Shares [%]: Scenario A - 2020-2024	
Figure 41 - Regional Market Shares [%]: Scenario B - 2020-2024	
Figure 42 - Regional Markets' Size [\$M]: Scenarios A and B - 2020-2024	
Figure 43 - National Markets Size [\$M]: Scenario A - 2020-2024	
Figure 44 - National Markets Shares [%]: Scenario A - 2020-2024	
Figure 45 - National Markets Size [\$M]: Scenario B - 2020-2024	
Figure 46 - National Markets Shares [%]: Scenario B - 2020-2024	122
Figure 47 - COVID-19 National Markets Size [\$M]: Scenarios A and B -	
2020-2024	122

COVID-19 Mitigation Products

(PPE, Serologic Test, Contact Tracing System, COVID-19 Drugs, COVID-19 Vaccine, Polymerase Chain Reaction, PCR Test Kits, Blockchain Technologies, Surge Hospitals, Self-collection Swabs, AI, Personal Protection Gear, Teleradiology, Eye Protection, Ultrasound, Dialysis, CT, X-Ray, Medical Glass, Telemedicine, Face Shields, Gowns, Homecare, Gloves, E-Health, Robotic PCR, Antigen Test, Monoclonal Antibody, Face Masks, Therapeutic Drugs, ICU, PACS, Contact Tracing, PPE Sterilization and More)

Market Research, to 2024

Vol.2

Table of Contents

PR	ODUCT/SER	RVICE MARKETS	32
1	COVID-19	Vaccines Market – 2020-2024	32
		VID-19 Vaccines Market Background	
	1.1.1	Introduction	
	1.1.2	Global COVID-19 Vaccine Development Funding	
	1.1.3	Vaccines Prices	
	1.1.4	COVID-19 Vaccines Market: Conclusions	
	1.1.5	COVID-19 Vaccines:Business Opportunities	
	1.1.6	COVID-19 Vaccines: Competitive Analysis: : Barriers to	
		Entry, Supplier Power, Buyer Power and Substitution	54
	1.1.7	Present and Potential Vendors	
	1.2 Glol	bal COVID-19 Pandemic Mitigation: Vaccines Market –	
		0-2024	58
	1.2.1	Vaccines COVID-19 Pandemic Mitigation Market – 2020-2024: Scenario A	
	1.2.2	Vaccines COVID-19 Pandemic Mitigation Market –	50
	1.2.2	2020-2024: Scenario B	59
			00
2		Post-Infection Therapeutic Drugs Market – 2020-	
			60
		VID-19 Post-Infection Therapies Drugs Market	
		kground	
	2.1.1	Introduction	
	2.1.2	Computer Aided COVID-19 Drug Research	
	2.1.3	Adaptive Designs For COVID-19 Clinical Trials	
	2.1.4	COVID-19 Therapeutic Drugs Market: Conclusions	
	2.1.5	COVID-19 Therapeutic Drug :Business Opportunities	69
	2.1.6	COVID-19 Post-Infection Therapeutic Drug:	
		Competitive Analysis: Barriers to Entry, Supplier Power,	
		Buyer Power and Substitution	
	2.1.7	Present and Potential Vendors	71
		bal COVID-19 Post-Infection Therapeutic Drugs Market	
	_ `	020-2024	74
	2.2.1	COVID-19 Post Infection Therapeutic Drugs Market –	
		2020-2024: Scenario A	/4
	2.2.2	Therapeutic Drugs COVID-19 Pandemic Mitigation	
		Market – 2020-2024: Scenario B	75
3	Other Pha	rma Industry Products COVID-19 Pandemic	
		Market - 2020-2024	76
		er COVID-19 Pharma Industry Products Market	
		kground	76
	3.1.1	Introduction and Findings	
	3.1.2	Other COVID-19 Pharma Industry Products Market:	
		Conclusions	78

	3.1.3	Other COVID-19 Pharma Industry Products:	
		Competitive Analysis: Barriers to Entry, Supplier Power,	
	_	Buyer Power and Substitution	79
		oal COVID-19 Pandemic Mitigation: Other Pharma	
		ıstry Products Market – 2020-2024	80
	3.2.1	Other Pharma Industry Products COVID-19 Pandemic	
		Mitigation Market – 2020-2024: Scenario A	80
	3.2.2	Other Pharma Industry Products COVID-19 Pandemic	
		Mitigation Market – 2020-2024: Scenario B	80
4	PCR Instru	umentation & Software COVID-19 Pandemic	
	Mitigation	Market - 2020-2024	82
		VID-19 PCR Instrumentation & Software Market	
		kground	82
	4.1.1	Introduction	
	4.1.2	PCR Technologies & Procedures	
	4.1.3	PCR Advantages	
	4.1.4	PCR Limitations	
	4.1.5	PCR Based Coronavirus Diagnostics Used and	
		Developed During January – April 2020	90
	4.1.6	Efforts to Develop and Disseminate a Test for COVID-	
	1.1.0	19	91
	4.1.7	PCR Purchasing Considerations	
	4.1.8	Costs of PCR Testing	
	4.1.9	PCR Instrumentation & Software Market: Conclusions	
	4.1.10	PCR Instrumentation & Software: Business	
	4.1.10	Opportunities	0.4
	4.1.11	PCR Instrumentation & Software: Competitive Analysis:	34
	4.1.11	Barriers to Entry, Supplier Power, Buyer Power and	
		Substitution	05
	4.1.12	Key Vendors	
			90
		oal COVID-19 Pandemic Mitigation: PCR rumentation & Software Market – 2020-2024	06
	4.2.1	PCR Instrumentation & Software COVID-19 Pandemic	90
	4.2.1		07
	4.0.0	Mitigation Market – 2020-2024: Scenario A	97
	4.2.2	PCR Instrumentation & Software COVID-19 Pandemic	07
		Mitigation Market – 2020-2024: Scenario B	97
5	Robotic P	CR Systems & Software COVID-19 Pandemic	
	Mitigation	Market – 2020-2024	98
	5.1 CO\	VID-19 Robotic PCR Systems & Software Market	
	Bac	kground	98
	5.1.1	Introduction and Findings	98
	5.1.2	Pooling PCR Method Testing Over 60 Samples	
		Simultaneously	102
	513		100

	5.1.4	Robotic PCR Systems & Software: Business	
		Opportunities	103
	5.1.5	Robotic PCR Systems & Software: Competitive	
		Analysis: Barriers to Entry, Supplier Power, Buyer	404
	5.0 Olah	Power and Substitution	104
	5.2 Globa	al COVID-19 Pandemic Mitigation: Robotic PCR ems & Software Market – 2020-2024	105
	5,2,1	Robotic PCR Systems & Software COVID-19 Pandemic	105
	5.2.1	Mitigation Market – 2020-2024: Scenario A	105
	5.2.2	Robotic PCR Systems & Software COVID-19 Pandemic	100
	0.2.2	Mitigation Market – 2020-2024: Scenario B	106
6	DCD Doogo		
0		nts & Consumables COVID-19 Pandemic Market – 2020-2024	107
		D-19 PCR Reagents & Consumables Market	107
		groundground	107
	6.1.1	Introduction	
	6.1.2	PCR Reagents & Consumables Market: Conclusions	
	6.1.3	PCR Reagents & Consumables: Business	
		Opportunities	109
	6.1.4	PCR Reagents & Consumables: Competitive Analysis:	
		Barriers to Entry, Supplier Power, Buyer Power and	
		Substitution	110
	6.2 1.2 G	llobal COVID-19 Pandemic Mitigation: PCR Reagents	444
		nsumables Market – 2020-2024	111
	6.2.1	PCR Reagents & Consumables COVID-19 Pandemic	111
	6.2.2	Mitigation Market – 2020-2024: Scenario A PCR Reagents & Consumables COVID-19 Pandemic	
	0.2.2	Mitigation Market – 2020-2024: Scenario B	112
_		-	1 12
7		uth Swabs COVID-19 Pandemic Mitigation Market	440
		1	
	7.1 COVI	ID-19 Nose & Mouth Swabs Market BackgroundIntroduction and Findings	
	7.1.1 7.1.2	Nose & Mouth Swabs: Competitive Analysis: Barriers to	113
	7.1.2	Entry, Supplier Power, Buyer Power and Substitution	116
	7.2 Globa	al COVID-19 Pandemic Mitigation: Nose & Mouth	
		os Market – 2020-2024	117
	7.2.1	Nose & Mouth Swabs COVID-19 Pandemic Mitigation	
		Market – 2020-2024: Scenario A	117
	7.2.2	Nose & Mouth Swabs COVID-19 Pandemic Mitigation	
		Market – 2020-2024: Scenario B	117
8	Self-collect	ion PCR Test Kits COVID-19 Pandemic Mitigation	
	Market - 20	20-2024	119
		D-19 Self-collection PCR Test Kits Market	
		ground	119
	8.1.1	Saliva Tests	120

		Mitigation Market – 2020-2024: Scenario A	123
9		gic Test Kits COVID-19 Pandemic Mitigation Market –	
		COVID-19 Serologic Test Kits Market Background	
	9.1.1 9.1.2	Introduction and Findings	124
	9.1.3	` ,	
	9.1.4		
	9.1.5		
		<u> </u>	137
	9.1.6	J , , , , , , , , , , , , , , , , , , ,	120
	0.45	Entry, Supplier Power, Buyer Power and Substitution	
		7 Key Vendors	
	9.2.1		
	9.2.2		
10	Stando	off Thermometry COVID-19 Pandemic Mitigation	
		= 2020-2024	141
		COVID-19 Standoff Thermometry Market Background	
		.1 Introduction and Findings	
		.2 Standoff Thermometry Market: Conclusions	
		.3 Standoff Thermometry: Business Opportunities	
		.4 Key Vendors	
		Global COVID-19 Pandemic Mitigation: Standoff	1 10
		Thermometry Market – 2020-2024	145
	10.2		
	10.2		
			140
11		Procedures COVID-19 Pandemic Mitigation Market –	1.17
		024	
		COVID-19 X-Ray Procedures Market Background	
	11.1		
	11.1	,	
	11.1		153
		Global CÓVID-19 Pandemic Mitigation: X-Ray Procedures Market – 2020-2024	153
	I	VIDINGL - ZUZU-ZUZ4	103

	11.2.1	X-Ray Procedures COVID-19 Pandemic Mitigation	
		Market – 2020-2024: Scenario A	154
	11.2.2	X-Ray Procedures COVID-19 Pandemic Mitigation	
		Market – 2020-2024: Scenario B	154
12	CT Proced	ures COVID-19 Pandemic Mitigation Market –	
			155
	12.1 COV	ID-19 CT Procedures Market Background	155
	12.1.1	Introduction and Findings	155
	12.1.2		
	12.1.3		
	12.1.4		159
	12.2 Glob	al CÓVID-19 Pandemic Mitigation: CT Procedures	4=0
		ket – 2020-2024	159
	12.2.1	CT Procedures COVID-19 Pandemic Mitigation Market	400
	40.00	- 2020-2024: Scenario A	160
	12.2.2	CT Procedures COVID-19 Pandemic Mitigation Market – 2020-2024: Scenario B	160
			100
13		l Procedures COVID-19 Pandemic Mitigation	
		020-2024	
		ID-19 Ultrasound Procedures Market Background	
	13.1.1	3	162
	13.1.2	• • • • • • • • • • • • • • • • • • • •	404
	10.1.0	Based Coronavirus Chest Ultrasound	
	13.1.3 13.1.4	COVID-19 Chest Ultrasound DiagnosticsUltrasound Procedures Market: Conclusions	
	13.1.4		
	13.1.5	Ultrasound Procedures: Business Opportunities Key Vendors	
		al COVID-19 Pandemic Mitigation: Ultrasound	100
	Proc	edures Market – 2020-2024	167
	13.2.1	Ultrasound Procedures COVID-19 Pandemic Mitigation	107
		Market – 2020-2024: Scenario A	167
	13.2.2	Ultrasound Procedures COVID-19 Pandemic Mitigation	
		Market – 2020-2024: Scenario B	
14	Wastowato	er Testing COVID-19 Pandemic Mitigation Market –	
14	2020-2024		160
		ID-19 Wastewater Testing Market Background	
	14.1.1	Introduction and Findings	
	14.1.2	FDG-PET/CT Procedures	
	14.1.3	COVID-19 Wastewater Testing	
	14.1.4	Wastewater Testing Market: Conclusions	
	14.1.5	Wastewater Testing: Business Opportunities	
	14.1.6	Key Vendors	
		al COVID-19 Pandemic Mitigation: Wastewater Testing	
		ret – 2020-2024	173

	14.2.1	Wastewater Testing COVID-19 Pandemic Mitigation	
		Market – 2020-2024: Scenario A	174
	14.2.2	Wastewater Testing COVID-19 Pandemic Mitigation	47/
		Market – 2020-2024: Scenario B	174
15		eleradiology COVID-19 Pandemic Mitigation	
		020-2024	
		S & Teleradiology Market Background	
	15.1.1	Introduction and Findings	176
	15.1.2	The FDA PACS & Teleradiography COVID-19	
		Pandemic Policy	180
	15.1.3	0 ,	
	15.1.4		
	15.1.5		182
	15.2 Glob	al COVID-19 Pandemic Mitigation: PACS &	
		radiologyMarket – 2020-2024	182
	15.2.1	PACS & TeleradiologyCOVID-19 Pandemic Mitigation	
		Market – 2020-2024: Scenario A	183
	15.2.2	PACS & TeleradiologyCOVID-19 Pandemic Mitigation	
		Market – 2020-2024: Scenario B	183
16	PPE Gown	s COVID-19 Pandemic Mitigation Market – 2020-	
	2024		184
	16.1 Pand	demic PPE Gowns Market Background	184
	16.1.1	Introduction and Findings	184
	16.1.2	PPE Gowns Market: Conclusions	190
	16.1.3	PPE Gowns: Business Opportunities	190
	16.2 Glob	al COVID-19 Pandemic Mitigation: PPE Gowns Market	
	- 20	20-2024	191
	16.2.1	PPE Gowns COVID-19 Pandemic Mitigation Market –	
		2020-2024: Scenario A	191
	16.2.2	PPE Gowns COVID-19 Pandemic Mitigation Market –	
		2020-2024: Scenario B	192
17	Gloves CO	VID-19 Pandemic Mitigation Market – 2020-2024	193
		ID-19 Gloves Market Background	
	17.1.1	Introduction and Findings	
	17.1.2	Gloves Market: Conclusions	
	17.1.3	Gloves: Business Opportunities	
	17.2 Glob	al COVID-19 Pandemic Mitigation: Gloves Market –	
)-2024	195
	17.2.1	Gloves COVID-19 Pandemic Mitigation Market – 2020-	
		2024: Scenario A	195
	17.2.2	Gloves COVID-19 Pandemic Mitigation Market – 2020-	
		2024: Scenario B	196
18	Face Mack	s COVID-19 Pandemic Mitigation Market – 2020-	
10	2024	5 55 FID 15 Fallacinic Milligation Market - 2020	107

	18.1 Med	ical Face Masks Market Background	197
	18.1.1	Introduction and Findings	
	18.1.2	N95 Masks Vs. Surgical Mask	198
	18.1.3	Face Masks Precautions	
	18.1.4	Face Masks Market: Conclusions	204
	18.1.5	Face Masks: Business Opportunities	
	18.1.6		204
		oal COVID-19 Pandemic Mitigation: Face Masks Market	
		20-2024	205
	18.2.1	Face Masks COVID-19 Pandemic Mitigation Market –	
	4000	2020-2024: Scenario A	206
	18.2.2	3	000
		2020-2024: Scenario B	206
19	Medical Fa	ce Shields COVID-19 Pandemic Mitigation Market	
	– 2020-202	4	207
	19.1 Med	ical Face Shields Market Background	
	19.1.1	Introduction and Findings	
	19.1.2	Face Shields Standards	209
	19.2 Glob	oal COVID-19 Pandemic Mitigation: Medical Face	
		lds Market – 2020-2024	210
	19.2.1	Medical Face Shields COVID-19 Pandemic Mitigation	
	4000	Market – 2020-2024: Scenario A	210
	19.2.2	3	044
		Market – 2020-2024: Scenario B	211
20	Eye Protec	ction COVID-19 Pandemic Mitigation Market –	
	2020-2024		
	20.1 Pand	demic Eye Protection Market Background	212
	20.1.1	Introduction and Findings	
	20.1.2	J	213
		oal COVID-19 Pandemic Mitigation: Eye Protection	
		ket – 2020-2024	
	20.2.1	Eye Protection COVID-19 Pandemic Mitigation Market	
		- 2020-2024: Scenario A	214
	20.2.2	Eye Protection COVID-19 Pandemic Mitigation Market	0.4=
		- 2020-2024: Scenario B	215
21	PPE Sterili	ization: Systems & Consumables COVID-19	
		Mitigation Market - 2020-2024	216
		oal COVID-19 Pandemic Mitigation: PPE Sterilization:	
	Syst	ems & Consumables Market – 2020-2024	216
	21.1.1	PPE Sterilization: Systems & Consumables COVID-19	
		•	216
	21.1.2	PPE Sterilization: Systems & Consumables COVID-19	
		Pandemic Mitigation Market - 2020-2024: Scenario B	217

22	Hand & Su	rface Sanitizers COVID-19 Pandemic Mitigation	
		020-2024	218
		d & Surface Sanitizers Market Background	
		al COVID-19 Pandemic Mitigation: Hand & Surface	= 10
		tizers Market – 2020-2024	221
		Hand & Surface Sanitizers COVID-19 Pandemic	∠∠ ۱
	22.2.1		004
		Mitigation Market – 2020-2024: Scenario A	221
	22.2.2	Hand & Surface Sanitizers COVID-19 Pandemic	
		Mitigation Market – 2020-2024: Scenario B	222
23	Sterilizatio	n COVID-19 Pandemic Mitigation Market – 2020-	
	2024	<u> </u>	223
	23.1 Steri	lization Market Background	
	23.1.1	Introduction	
	23.1.2	Definitions	
	23.1.2	Timing and Location Of Cleaning And Disinfection Of	∠∠¬
	23.1.3		224
	00.4.4	Surfaces	
	23.1.4	Hard (Non-porous) Surfaces	
	23.1.5	Soft (Porous) Surfaces	
	23.1.6	Electronics	225
	23.1.7	Linens, Clothing, and Other Items That Go in the	
		Laundry	226
	23.1.8	Risk of Exposure	226
	23.1.9	Considerations for Employers	227
	23.1.10	Sterilization Market: Conclusions	
	23.2 Glob	al COVID-19 Pandemic Mitigation: Sterilization Market	
		20-2024	228
	23.2.1	Sterilization COVID-19 Pandemic Mitigation Market –	
	20.2.1	2020-2024: Scenario A	229
	23.2.2	Sterilization COVID-19 Pandemic Mitigation Market –	223
	23.2.2	2020-2024: Scenario B	220
		2020-2024. Scenario B	229
24	Other Pers	onal Protection Gear COVID-19 Pandemic	
	Mitigation	Market - 2020-2024	231
	24.1 Glob	al COVID-19 Pandemic Mitigation: Other Personal	
		ection Gear Market – 2020-2024	231
	24.1.1	Other Personal Protection Gear COVID-19 Pandemic	20 .
	27.1.1	Mitigation Market – 2020-2024: Scenario A	221
	24.1.2	Other Personal Protection Gear COVID-19 Pandemic	231
	24.1.2		222
		Mitigation Market – 2020-2024: Scenario B	232
25	AI, Big Dat	a & Deep Learning COVID-19 Pandemic Mitigation	
		020-2024	233
		demic AI, Big Data & Deep Learning Market	
		ground	233
	25.1.1		233
	25.1.2		
	25.1.2		
	٠٠١١٠٠		∠∪∪

	25.1.4	Data Dashboards	237
	25.1.5	Diagnosis and Prognosis	
	25.1.6	COVID-19 Treatments Optimization	
	25.1.7	COVID-19 Pandemic Social Control	
	25.1.8	Pandemic Outbreak Forecasting	240
	25.1.9	AI, Big-Data and Deep Learning Assisted CT Imaging	
	25.1.10	AI, Big-Data and Deep-Learning Assisted COVID-19	
		Treatment	243
	25.1.11	COVID-19: Al Assisted X-rays Imaging	244
	25.1.12	COVID-19 AI, Big Data & Deep Learning	244
	25.1.13	Al Assisted Pandemic Symptoms Analysis	
	25.1.14	AI, Big Data & Deep Learning Market: Conclusions	247
	25.1.15	AI, Big Data & Deep Learning: Business Opportunities	248
	25.1.16	Key Vendors	248
	25.2 Glob	al COVID-19 Pandemic Mitigation: AI, Big Data &	
		Learning Market – 2020-2024	250
	25.2.1	AI, Big Data & Deep Learning COVID-19 Pandemic	
		Mitigation Market – 2020-2024: Scenario A	250
	25.2.2	AI, Big Data & Deep Learning COVID-19 Pandemic	
		Mitigation Market – 2020-2024: Scenario B	250
26	Homecare	IT COVID-19 Pandemic Mitigation Market – 2020-	
20			252
		lemic Homecare IT Market Background	
	26.1.1	Introduction and Findings	
	26.1.2		
	26.1.3		
	26.1.4	Key Vendors	
		al COVID-19 Pandemic Mitigation: Homecare IT	
		et – 2020-2024	255
	26.2.1	Homecare IT COVID-19 Pandemic Mitigation Market –	
		2020-2024: Scenario A	255
	26.2.2	Homecare IT COVID-19 Pandemic Mitigation Market –	
		2020-2024: Scenario B	255
27	Contact Tr	oning Systems & Sarvises COVID 40 Bandamia	
21	Mitigation	acing Systems & Services COVID-19 Pandemic Market – 2020-2024	257
		Hemic Contact Tracing Systems & Services Market	257
		groundg Systems & Services Market	257
	27.1.1	Introduction and Findings	
	27.1.1		
	27.1.2	MIT "Private Kit" The UK NHS COVID-19 App	
	27.1.3 27.1.4	Companies Making Cell Location Tracking Technology	
			200
		al COVID-19 Pandemic Mitigation: Contact Tracing ems & Services Market – 2020-2024	270
	27.2.1	Contact Tracing Systems & Services COVID-19	∠ / ∪
	۷۱ .۷. ۱	Pandemic Mitigation Market – 2020-2024: Scenario A	271
		i anucinio ivilligation iviainci – 2020-2024. Scendilo A	∠/

	27.2.2	Contact Tracing Systems & Services COVID-19 Pandemic Mitigation Market – 2020-2024: Scenario B	271
28		OVID-19 Pandemic Mitigation Market – 2020-2024	
		demic E-Health Market Background	
	28.1.1	Introduction and Findings	
	28.1.2		
	28.1.3	• •	
	28.1.4	Key Vendors	275
		oal COVID-19 Pandemic Mitigation: E-Health Market – 0-2024	275
	28.2.1	E-Health COVID-19 Pandemic Mitigation Market –	
	20.2.1	2020-2024: Scenario A	276
	28.2.2	E-Health COVID-19 Pandemic Mitigation Market –	7 0
	20.2.2	2020-2024: Scenario B	276
29		n Technologies COVID-19 Pandemic Mitigation	
		020-2024	
		demic Blockchain Technologies Market Background	
	29.1.1	Introduction and Findings	
	29.1.2	Blockchain in Healthcare	
	29.1.3	Blockchain Applications	279
	29.1.4	Blockchain Technologies Market: Conclusions	282
	29.1.5	Blockchain Technologies: Business Opportunities	283
	29.1.6	Key Vendors	283
	29.2 Glob	pal COVID-19 Pandemic Mitigation: Blockchain	
		nnologies Market – 2020-2024	284
	29.2.1	Blockchain Technologies COVID-19 Pandemic	
		Mitigation Market – 2020-2024: Scenario A	284
	29.2.2	Blockchain Technologies COVID-19 Pandemic	
		Mitigation Market – 2020-2024: Scenario B	285
30	Other ICT	COVID-19 Pandemic Mitigation Market – 2020-	
			286
		er Pandemics ICT Market Background	
	30.1.1	Introduction and Findings	
	30.1.2	Other ICT Market: Conclusions	
	30.1.3	Other ICT: Business Opportunities	
	30.1.3	Vendors	
		pal COVID-19 Pandemic Mitigation: Other ICT Market –	209
		0-2024	200
			290
	30.2.1	Other ICT COVID-19 Pandemic Mitigation Market –	004
	00.00	2020-2024: Scenario A	291
	30.2.2	Other ICT COVID-19 Pandemic Mitigation Market –	
		2020-2024: Scenario B	291
31	Noninvasi	ve Ventilators COVID-19 Pandemic Mitigation	
		020.2024	202

	31.1 Non-I	nvasive Ventilators Market Background	293
	31.1.1	Introduction and Findings	
	31.1.2	The U.S. HHS Procurement Contracts On Non-Invasive	
		Ventilators With Ten Vendors	299
	31.1.3	Helmet-Based Non-invasive Ventilators	299
	31.1.4	Non-invasive Ventilators Market: Conclusions	300
	31.1.5	Business Opportunities	301
	31.1.6	Non-invasive Ventilators: Competitive Analysis:	
		Barriers to Entry, Supplier Power, Buyer Power and	
		Barriers to Substitution	302
	31.1.7	Key Vendors	303
	31.2 Globa	al COVID-19 Pandemic Mitigation: Noninvasive	
	Ventil	ators Market – 2020-2024	303
	31.2.1	Noninvasive Ventilators COVID-19 Pandemic Mitigation	
		Market – 2020-2024: Scenario A	303
	31.2.2	Noninvasive Ventilators COVID-19 Pandemic Mitigation	
		Market – 2020-2024: Scenario B	304
32	Invasive Me	chanical Ventilators COVID-19 Pandemic	
J Z		Market – 2020-2024	305
		ive Mechanical Ventilators Market Background	
	32.1.1	Introduction and Findings	
	32.1.1	Challenges of Traditional Mechanical Ventilation	505
	JZ. 1.Z	Devices	312
	32.1.2.1		
		Complex and Time Consuming To Administer Care	
	32.1.2.3	· · · · · · · · · · · · · · · · · · ·	
	32.1.3	Invasive Mechanical Ventilators Market: Conclusions	
	32.1.4	Invasive Mechanical Ventilators: Business	
	02.1. 4	Opportunities	313
	32.1.5	Invasive Mechanical Ventilators: Competitive Analysis:	
	02.1.0	Barriers to Entry, Supplier Power, Buyer Power and	
		Barriers to Substitution	315
	32.1.6	Key Vendors	
		Il COVID-19 Pandemic Mitigation: Invasive	
	Mech	anical Ventilators Market – 2020-2024	316
	32.2.1	Invasive Mechanical Ventilators COVID-19 Pandemic	
	02.2	Mitigation Market – 2020-2024: Scenario A	316
	32.2.2	Invasive Mechanical Ventilators COVID-19 Pandemic	
	V	Mitigation Market – 2020-2024: Scenario B	317
00	Name Orași		
33		ation Ventilators COVID-19 Pandemic Mitigation	040
	Warket – 20	20-2024	318
		Generation Ventilators Market Background	
	33.1.1	Introduction and Findings	
	33.1.2	Next Generation Ventilators Market: Conclusions	
	33.1.3	Next Generation Ventilators: Business Opportunities	320

	33.1.4	Next Generation Ventilators: Competitive Analysis:	
		Barriers to Entry, Supplier Power, Buyer Power and	004
	00.0	Barriers to Substitution	321
		oal COVID-19 Pandemic Mitigation: Next Generation	200
		tilators Market – 2020-2024	322
	33.2.1	Next Generation Ventilators COVID-19 Pandemic	222
	22.2.2	Mitigation Market – 2020-2024: Scenario A Next Generation Ventilators COVID-19 Pandemic	322
	33.2.2		222
		Mitigation Market – 2020-2024: Scenario B	322
34		"ICU" (Equipment, Software, Services) COVID-19	
		Mitigation Market – 2020-2024	324
		/ID-19 Homecare "ICU" (Equipment, Software,	
		vices) Market Background	324
	34.1.1	Introduction and Findings	
	34.1.2	WHO Protocol For COVID-19 Homecare	
	34.1.3	Homecare Market: Conclusions	
	34.1.4	Homecare Business Opportunities	329
	34.1.5	Homecare: Competitive Analysis: Barriers to Entry,	
		Supplier Power, Buyer Power and Barriers to	
		Substitution	
	34.1.6	Key Vendors	331
		pal COVID-19 Pandemic Mitigation: Homecare "ICU"	004
		uipment, Software, Services) Market – 2020-2024	331
	34.2.1	Homecare "ICU" (Equipment, Software, Services)	
		COVID-19 Pandemic Mitigation Market – 2020-2024:	200
	24.0.0	Scenario A	332
	34.2.2	Homecare "ICU" (Equipment, Software, Services)	
		COVID-19 Pandemic Mitigation Market – 2020-2024: Scenario B	222
	2/12 Dort	able Ventilators Market Background	
	34.3.1	Introduction and Findings	
	34.3.1	Portable Ventilators Market: Conclusions	
	34.3.3	Key Vendors	
		pal COVID-19 Pandemic Mitigation: Mobile Ventilators	
		ket – 2020-2024	337
	34.4.1	Mobile Ventilators COVID-19 Pandemic Mitigation	
	04.4.1	Market – 2020-2024: Scenario A	337
	34.4.2	Mobile Ventilators COVID-19 Pandemic Mitigation	
	01.1.2	Market – 2020-2024: Scenario B	338
35		pacity Hospitals & Surge ICUsCOVID-19 Pandemic	
		Market – 2020-2024	
	_	ge Capacity Hospitals & Surge ICUsMarket Background	
	35.1.1	O	339
	35.1.2	Surge Capacity Hospitals & Surge ICUsMarket:	242

		oal COVID-19 Pandemic Mitigation: Surge Capacity oitals & Surge ICUsMarket – 2020-2024 Surge Capacity Hospitals & Surge ICUsCOVID-19	342
	35.2.2	Pandemic Mitigation Market – 2020-2024: Scenario A Surge Capacity Hospitals & Surge ICUsCOVID-19	342
	00.2.2	Pandemic Mitigation Market – 2020-2024: Scenario B	343
36		alysis COVID-19 Pandemic Mitigation Market –	
	2020-2024		344
		ey Dialysis Systems Market Background	
	36.1.1	Introduction and Findings	
	36.1.2	Kidney Dialysis Systems Market: Conclusions	
	36.1.3	Kidney Dialysis Systems: Business Opportunities	
	36.1.4	Key Vendors	347
		oal COVID-19 Pandemic Mitigation: Kidney Dialysis	
		ket – 2020-2024	348
	36.2.1	Kidney DialysisCOVID-19 Pandemic Mitigation Market – 2020-2024: Scenario A	348
	36.2.2	Kidney DialysisCOVID-19 Pandemic Mitigation Market – 2020-2024: Scenario B	349
-	= .		0 10
37		oreal Membrane Oxygenation Procedures COVID-	0.50
		nic Mitigation Market – 2020-2024	350
		acorporeal Membrane Oxygenation Procedures Market	250
		kground	
	37.1.1	Introduction and Findings	350
	37.1.2	The FDA Extracorporeal Membrane Oxygenation (ECMO) Policy	353
	37.1.3	Extracorporeal Membrane Oxygenation Procedures Market: Conclusions	354
	37.1.4	Extracorporeal Membrane Oxygenation Procedures:	
	07.4.5	Business Opportunities	
	37.1.5	Key Vendors	355
	37.2 GIOD	pal CÓVID-19 Pandemic Mitigation: Extracorporeal	250
		hbrane Oxygenation Procedures Market – 2020-2024	356
	37.2.1	Extracorporeal Membrane Oxygenation Procedures	
		COVID-19 Pandemic Mitigation Market – 2020-2024:	250
	37.2.2	Scenario A Extracorporeal Membrane Oxygenation Procedures	356
	31.2.2	COVID-19 Pandemic Mitigation Market – 2020-2024:	
		Scenario B	356
38		nsive Care Modalities COVID-19 Pandemic	
		Market - 2020-2024	
		er Intensive Care Modalities Market Background	
	38.1.1	Introduction and Findings	
	38.1.2	Other Intensive Care Modalities Market: Conclusions	361

	38.2 Global	COVID-19 Pandemic Mitigation: Other Intensive	
	Care M	Modalities Market – 2020-2024	362
		Other Intensive Care Modalities COVID-19 Pandemic	
		Mitigation Market – 2020-2024: Scenario A	362
		Other Intensive Care Modalities COVID-19 Pandemic	
		Mitigation Market – 2020-2024: Scenario B	362
39	Gowns Manu	rfacturing Plants COVID-19 Pandemic Mitigation	
		0-2024	364
		owns Manufacturing Plants Market Background	
		Introduction and Findings	
		Gowns Manufacturing Plants Market: Conclusions	
		Gowns Manufacturing Plants: Business Opportunities	
		COVID-19 Pandemic Mitigation: Gowns	000
		acturing Plants Market – 2020-2024	366
		Gowns Manufacturing Plants COVID-19 Pandemic	000
		Mitigation Market – 2020-2024: Scenario A	367
		Gowns Manufacturing Plants COVID-19 Pandemic	
		Mitigation Market – 2020-2024: Scenario B	367
40		_	
40		ufacturing Plants COVID-19 Pandemic Mitigation	200
		0-2024	369
		al PPE Gloves Manufacturing Plants Market	260
	Dackyi	ound	ანყ ივი
		Introduction and Findings	309
		Medical PPE Gloves Manufacturing Plants Market: Conclusions	271
			311
		Medical PPE Gloves Manufacturing Plants: Business Opportunities	272
		COVID-19 Pandemic Mitigation: Gloves	312
		acturing Plants Market – 2020-2024	372
		Gloves Manufacturing Plants COVID-19 Pandemic	51 2
		Mitigation Market – 2020-2024: Scenario A	373
		Gloves Manufacturing Plants COVID-19 Pandemic	57 5
		Mitigation Market – 2020-2024: Scenario B	373
		_	07 0
41		Manufacturing Plants COVID-19 Pandemic	
		arket – 2020-2024	
		Masks Manufacturing Plants Market Background	
		Introduction and Findings	
		N95 Respirators Manufacturing	
		Face Masks Manufacturing Plants Market: Conclusions.	385
		Face Masks Manufacturing Plants: Business	000
		Opportunities	
		Key VendorsMitigation, Face Masks	386
		COVID-19 Pandemic Mitigation: Face Masks	387
	IVIANLITA	aciunno Piants Market – 7070-7074	.≾ಜ./

	41.2.1	Face Masks Manufacturing Plants COVID-19 Pandemic Mitigation Market – 2020-2024: Scenario A	387
	41.2.2	Face Masks Manufacturing Plants COVID-19 Pandemic Mitigation Market – 2020-2024: Scenario B	387
42	Mitigation M 42.1 Face 42.1.1 42.2 Globa	Is Manufacturing Plants COVID-19 Pandemic Market – 2020-2024 Shields Manufacturing Plants Market Background Introduction and Findings Face Shields Manufacturing Plants COVID-19 Pandemic Mitigation Market – 2020-2024: Scenario A Face Shields Manufacturing Plants COVID-19 Pandemic Mitigation Market – 2020-2024: Scenario B	389 389 391
43	Pandemic M 43.1 Serol Backs 43.1.1 43.1.2	ditigation Market – 2020-2024	393 393 394 395
44	Pandemic M 44.1 Melt-l Backs 44.1.1 44.1.2	PPE Fabric Manufacturing Plants COVID-19 Mitigation Market – 2020-2024 Blown PPE Fabric Manufacturing Plants Market ground	397 397 401 402
45		PPE Fabric Manufacturing Plants COVID-19	405

	45.1 Spui	n-Bond PPE Fabric Manufacturing Plants Market	
	Back	kground	
	45.1.1	Introduction and Findings	405
	45.1.2	Spun-Bond PPE Fabric Manufacturing Plants Market:	
		Conclusions	406
		pal COVID-19 Pandemic Mitigation: Spun-Bond PPE	
	Fabr	ric Manufacturing Plants Market – 2020-2024	408
	45.2.1	Spun-Bond PPE Fabric Manufacturing Plants COVID-	
		19 Pandemic Mitigation Market – 2020-2024: Scenario	
		A	408
	45.2.2	Spun-Bond PPE Fabric Manufacturing Plants COVID-	
		19 Pandemic Mitigation Market – 2020-2024: Scenario	
		В	408
46	Self-collec	tion PCR Test Kits Manufacturing Plants COVID-	
		nic Mitigation Market – 2020-2024	410
		ket Background	
		oal COVID-19 Pandemic Mitigation: Self-collection PCR	
		: Kits Manufacturing Plants Market – 2020-2024	411
	46.2.1	Self-collection PCR Test Kits Manufacturing Plants	
		COVID-19 Pandemic Mitigation Market – 2020-2024:	
		Scenario A	411
	46.2.2	Self-collection PCR Test Kits Manufacturing Plants	
		COVID-19 Pandemic Mitigation Market – 2020-2024:	
		Scenario B	412
47	Ventilators	s Manufacturing Plants COVID-19 Pandemic	
	Mitigation	Market – 2020-2024	413
		tilators Manufacturing Plants Market Background	
	47.1.1		
	47.1.2		
	47.2 Glob	oal COVID-19 Pandemic Mitigation: Ventilators	
		ufacturing Plants Market – 2020-2024	417
	47.2.1	Ventilators Manufacturing Plants COVID-19 Pandemic	
		Mitigation Market – 2020-2024: Scenario A	418
	47.2.2	Ventilators Manufacturing Plants COVID-19 Pandemic	
		Mitigation Market – 2020-2024: Scenario B	418
48	PCP Page	ents Manufacturing Plants COVID-19 Pandemic	
40	_	Market – 2020-2024	<i>1</i> 10
		pal COVID-19 Pandemic Mitigation: PCR Reagents	+ 13
		ufacturing Plants Market – 2020-2024	4 10
	48.1.1	PCR Reagents Manufacturing Plants COVID-19	- 13
	10.1.1	Pandemic Mitigation Market – 2020-2024: Scenario A	419
	48.1.2	PCR Reagents Manufacturing Plants COVID-19	+10
	10.112	Pandemic Mitigation Market – 2020-2024: Scenario B	420

49		ms Manufacturing Plants COVID-19 Pandemic	
		Market – 2020-2024al COVID-19 Pandemic Mitigation: PCR Systems	421
		ufacturing Plants Market – 2020-2024	421
	49.1.1	PCR Systems Manufacturing Plants COVID-19	72 1
		Pandemic Mitigation Market – 2020-2024: Scenario A	421
	49.1.2		
		Pandemic Mitigation Market – 2020-2024: Scenario B	422
50	Nose & Mo	outh Swabs Manufacturing Plants COVID-19	
		Mitigation Market – 2020-2024	423
		e & Mouth Swabs Manufacturing Plants Market	
		kground	
	50.1.1		
	50.1.2	G	
	50.1.3		426
	50.2 Glob	pal COVID-19 Pandemic Mitigation: Nose & Mouth	400
	50.2.1	bs Manufacturing Plants Market – 2020-2024 Nose & Mouth Swabs Manufacturing Plants COVID-19	420
	30.2.1	Pandemic Mitigation Market – 2020-2024: Scenario A	427
	50.2.2	Nose & Mouth Swabs Manufacturing Plants COVID-19	127
	00.2.2	Pandemic Mitigation Market – 2020-2024: Scenario B	427
51	COVID-10	Vaccine Manufacturing Plants Mitigation Market –	
31		waccine Manufacturing Flants Mitigation Market –	428
		al COVID-19 Vaccine Manufacturing Plants Market –	
		D-2024	428
	51.1.1	COVID-19 Vaccine Manufacturing Plants Market –	
		2020-2024: Scenario A	428
	51.1.2	COVID-19 Vaccine Manufacturing Plants Market –	
		2020-2024: Scenario B	429
52	R&D Equip	oment & Consumables COVID-19 Pandemic	
	Mitigation	Market - 2020-2024	430
		al COVID-19 Pandemic Mitigation: R&D Equipment &	
		sumables Market – 2020-2024	430
	52.1.1	R&D Equipment & Consumables COVID-19 Pandemic	420
	52.1.2	Mitigation Market – 2020-2024: Scenario A	430
	J2.1.Z	Mitigation Market – 2020-2024: Scenario B	431
50	Ma Park Ol	_	401
53		ass and Other Products & Services COVID-19	422
		Mitigation Market – 2020-2024 ical Glass and Other Products & Services Market	432
		ground	4 32
	53.1.1	-	432
	53.1.2		
		Key Medical Glass Vendors	

53.2 G	lobal COVID-19 Pandemic Mitigation: Medical Glass and	
O	ther Products & Services Market – 2020-2024	433
53.2.1	Medical Glass and Other Products & ServicesCOVID-	
	19 Pandemic Mitigation Market – 2020-2024: Scenario	
	A	434
53.2.2	Medical Glass and Other Products & ServicesCOVID-	
	19 Pandemic Mitigation Market – 2020-2024: Scenario	
	В	434

List of Tables

Table 1 – Adult Vaccine 2020-2021 Price List	48
Table 2 – Adult Influenza Vaccine 2020-2021 Price List	49
Table 3 - Vaccines Market Size, Market Dynamics & Market Share: Scenario A - 2020-2024	58
Table 4 - Vaccines Market Size, Market Dynamics & Market Share:	
	59
Table 5 - Therapeutic Drugs Market Size, Market Dynamics & Market	
Share: Scenario A - 2020-2024	74
Table 6 - Therapeutic Drugs Market Size, Market Dynamics & Market	
Share: Scenario B - 2020-2024	75
Table 7 - Other Pharma Industry Products Market Size, Market Dynamics &	
Market Share: Scenario A - 2020-2024	80
Table 8 - Other Pharma Industry Products Market Size, Market Dynamics &	
Market Share: Scenario B - 2020-2024	80
Table 9 - PCR Instrumentation & Software Market Size, Market Dynamics	
& Market Share: Scenario A - 2020-2024	97
Table 10 - PCR Instrumentation & Software Market Size, Market Dynamics	
& Market Share: Scenario B - 2020-2024	97
Table 11 - Robotic PCR Systems & Software Market Size, Market	
Dynamics & Market Share: Scenario A - 2020-20241	05
Table 12 - Robotic PCR Systems & Software Market Size, Market	
Dynamics & Market Share: Scenario B - 2020-20241	06
Table 13 - PCR Reagents & Consumables Market Size, Market Dynamics	
& Market Share: Scenario A - 2020-20241	11
Table 14 - PCR Reagents & Consumables Market Size, Market Dynamics	40
& Market Share: Scenario B - 2020-2024	12
Table 15 - Nose & Mouth Swabs Market Size, Market Dynamics & Market	47
Share: Scenario A - 2020-2024	17
Table 16 - Nose & Mouth Swabs Market Size, Market Dynamics & Market	17
Share: Scenario B - 2020-2024	17
Table 17 - Self-collection PCR Test Kits Market Size, Market Dynamics & Market Share: Scenario A - 2020-2024	22
	23
Table 18 - Self-collection PCR Test Kits Market Size, Market Dynamics & Market Share: Scenario B - 2020-2024	23
Table 19 - Serologic Test Kits Market Size, Market Dynamics & Market	23
Share: Scenario A - 2020-20241	30
Table 20 - Serologic Test Kits Market Size, Market Dynamics & Market	JJ
Share: Scenario B - 2020-20241	4∩
Table 21 - Standoff Thermometry Market Size, Market Dynamics & Market	70
Share: Scenario A - 2020-20241	46
Table 22 - Standoff Thermometry Market Size, Market Dynamics & Market	
Share: Scenario B - 2020-20241	46
Table 23 - X-Ray Procedures Market Size, Market Dynamics & Market	
Share: Scenario A - 2020-2024	54

Table 24 - X-Ray Procedures Market Size, Market Dynamics & Market	
Share: Scenario B - 2020-2024	154
Table 25 - CT Procedures Market Size, Market Dynamics & Market Share:	
Scenario A - 2020-2024	160
Table 26 - CT Procedures Market Size, Market Dynamics & Market Share:	
Scenario B - 2020-2024	160
Table 27 - Ultrasound Procedures Market Size, Market Dynamics & Market	
Share: Scenario A - 2020-2024	167
Table 28 - Ultrasound Procedures Market Size, Market Dynamics & Market	
Share: Scenario B - 2020-2024	167
Table 29 - Wastewater Testing Market Size, Market Dynamics & Market	
Share: Scenario A - 2020-2024	174
Table 30 - Wastewater Testing Market Size, Market Dynamics & Market	
Share: Scenario B - 2020-2024	174
Table 31 - PACS & Teleradiology Market Size, Market Dynamics & Market	
Share: Scenario A - 2020-2024	183
Table 32 - PACS & Teleradiology Market Size, Market Dynamics & Market	
Share: Scenario B - 2020-2024	183
Table 33 - PPE Gowns Market Size, Market Dynamics & Market Share:	
Scenario A - 2020-2024	191
Table 34 - PPE Gowns Market Size, Market Dynamics & Market Share:	
Scenario B - 2020-2024	192
Table 35 - Gloves Market Size, Market Dynamics & Market Share:	
Scenario A - 2020-2024	195
Table 36 - Gloves Market Size, Market Dynamics & Market Share:	
Scenario B - 2020-2024	196
Table 37 - Face Masks Market Size, Market Dynamics & Market Share:	
Scenario A - 2020-2024	206
Table 38 - Face Masks Market Size, Market Dynamics & Market Share:	
Scenario B - 2020-2024	206
Table 39 - Medical Face Shields Market Size, Market Dynamics & Market	
Share: Scenario A - 2020-2024	210
Table 40 - Medical Face Shields Market Size, Market Dynamics & Market	
Share: Scenario B - 2020-2024	211
Table 41 - Eye Protection Market Size, Market Dynamics & Market Share:	
Scenario A - 2020-2024	214
Table 42 - Eye Protection Market Size, Market Dynamics & Market Share:	
Scenario B - 2020-2024	215
Table 43 - PPE Sterilization: Systems & Consumables Market Size, Market	
Dynamics & Market Share: Scenario A - 2020-2024	216
Table 44 - PPE Sterilization: Systems & Consumables Market Size, Market	
Dynamics & Market Share: Scenario B - 2020-2024	217
Table 45 - Hand & Surface Sanitizers Market Size, Market Dynamics &	
Market Share: Scenario A - 2020-2024	221
Table 46 - Hand & Surface Sanitizers Market Size, Market Dynamics &	
Market Share: Scenario B - 2020-2024	222

Table 47 - Sterilization Market Size, Market Dynamics & Market Share:	220
Scenario A - 2020-2024 Table 48 - Sterilization Market Size, Market Dynamics & Market Share:	229
Scenario B - 2020-2024	229
Table 49 - Other Personal Protection Gear Market Size, Market Dynamics	220
& Market Share: Scenario A - 2020-2024	231
Table 50 - Other Personal Protection Gear Market Size, Market Dynamics	_0.
& Market Share: Scenario B - 2020-2024	232
Table 51 - AI, Big Data & Deep Learning Market Size, Market Dynamics &	
Market Share: Scenario A - 2020-2024	250
Table 52 - AI, Big Data & Deep Learning Market Size, Market Dynamics &	
Market Share: Scenario B - 2020-2024	250
Table 53 - Homecare IT Market Size, Market Dynamics & Market Share:	
Scenario A - 2020-2024	255
Table 54 - Homecare IT Market Size, Market Dynamics & Market Share:	
Scenario B - 2020-2024	255
	260
Table 56 - Contact Tracing Systems & Services Market Size, Market	
Dynamics & Market Share: Scenario A - 2020-2024	271
Table 57 - Contact Tracing Systems & Services Market Size, Market	074
Dynamics & Market Share: Scenario B - 2020-2024	271
Table 58 - E-Health Market Size, Market Dynamics & Market Share:	070
Scenario A - 2020-2024	276
Table 59 - E-Health Market Size, Market Dynamics & Market Share: Scenario B - 2020-2024	276
Table 60 - Blockchain Technologies Market Size, Market Dynamics &	210
Market Share: Scenario A - 2020-2024	284
Table 61 - Blockchain Technologies Market Size, Market Dynamics &	204
Market Share: Scenario B - 2020-2024	285
Table 62 - Other ICT Market Size, Market Dynamics & Market Share:	
Scenario A - 2020-2024	291
Table 63 - Other ICT Market Size, Market Dynamics & Market Share:	
Scenario B - 2020-2024	291
Table 64 - Procurement Contracts on Non-Invasive Ventilators with Ten	
Vendors	299
Table 65 - Noninvasive Ventilators Market Size, Market Dynamics & Market	
Share: Scenario A - 2020-2024	303
Table 66 - Noninvasive Ventilators Market Size, Market Dynamics & Market	
Share: Scenario B - 2020-2024	304
Table 67 - Invasive Mechanical Ventilators Market Size, Market Dynamics	
& Market Share: Scenario A - 2020-2024	316
Table 68 - Invasive Mechanical Ventilators Market Size, Market Dynamics	
	317
Table 69 - Next Generation Ventilators Market Size, Market Dynamics &	
Market Share: Scenario A - 2020-2024	322

Table 70 - Next Generation Ventilators Market Size, Market Dynamics &	
Market Share: Scenario B - 2020-2024	322
Table 71 - Homecare "ICU" (Equipment, Software, Services) Market Size,	
Market Dynamics & Market Share: Scenario A - 2020-2024	332
Table 72 - Homecare "ICU" (Equipment, Software, Services) Market Size,	
Market Dynamics & Market Share: Scenario B - 2020-2024	332
Table 73 - Mobile Ventilators Market Size, Market Dynamics & Market	
Share: Scenario A - 2020-2024	337
Table 74 - Mobile Ventilators Market Size, Market Dynamics & Market	001
Share: Scenario B - 2020-2024	338
Table 75 - Surge Capacity Hospitals & Surge ICUsMarket Size, Market	550
Dynamics & Market Share: Scenario A - 2020-2024	342
·	542
Table 76 - Surge Capacity Hospitals & Surge ICUsMarket Size, Market	242
Dynamics & Market Share: Scenario B - 2020-2024	343
Table 77 - Kidney Dialysis Market Size, Market Dynamics & Market Share:	0.40
Scenario A - 2020-2024	348
Table 78 - Kidney Dialysis Market Size, Market Dynamics & Market Share:	0.40
Scenario B - 2020-2024	349
Table 79 - Extracorporeal Membrane Oxygenation Procedures Market	
Size, Market Dynamics & Market Share: Scenario A - 2020-	
2024	356
Table 80 - Extracorporeal Membrane Oxygenation Procedures Market	
Size, Market Dynamics & Market Share: Scenario B - 2020-	
2024	356
Table 81 - Other Intensive Care Modalities Market Size, Market Dynamics	
& Market Share: Scenario A - 2020-2024	362
Table 82 - Other Intensive Care Modalities Market Size, Market Dynamics	
& Market Share: Scenario B - 2020-2024	362
Table 83 - Gowns Manufacturing Plants Market Size, Market Dynamics &	
Market Share: Scenario A - 2020-2024	367
Table 84 - Gowns Manufacturing Plants Market Size, Market Dynamics &	
Market Share: Scenario B - 2020-2024	367
Table 85 - Gloves Manufacturing Plants Market Size, Market Dynamics &	
Market Share: Scenario A - 2020-2024	373
Table 86 - Gloves Manufacturing Plants Market Size, Market Dynamics &	
Market Share: Scenario B - 2020-2024	373
Table 87 - Face Masks Manufacturing Plants Market Size, Market	
Dynamics & Market Share: Scenario A - 2020-2024	387
Table 88 - Face Masks Manufacturing Plants Market Size, Market	
Dynamics & Market Share: Scenario B - 2020-2024	387
Table 89 - Face Shields Manufacturing Plants Market Size, Market	
Dynamics & Market Share: Scenario A - 2020-2024	391
Table 90 - Face Shields Manufacturing Plants Market Size, Market	
Dynamics & Market Share: Scenario B - 2020-2024	392
Table 91 – Serologic Test Kits Manufacturing Plants Market Size, Market	
Dynamics & Market Share: Scenario A - 2020-2024	395

Table 92 – Serologic Test Kits Manufacturing Plants Market Size, Market	
Dynamics & Market Share: Scenario B - 2020-2024	395
Table 93 - Melt-Blown PPE Fabric Manufacturing Plants Market Size,	
Market Dynamics & Market Share: Scenario A - 2020-20244	403
Table 94 - Melt-Blown PPE Fabric Manufacturing Plants Market Size,	
Market Dynamics & Market Share: Scenario B - 2020-2024	403
Table 95 - Spun-Bond PPE Fabric Manufacturing Plants Market Size,	
Market Dynamics & Market Share: Scenario A - 2020-2024	408
Table 96 - Spun-Bond PPE Fabric Manufacturing Plants Market Size,	
Market Dynamics & Market Share: Scenario B - 2020-2024	408
Table 97 - Self-collection PCR Test Kits Manufacturing Plants Market Size,	
Market Dynamics & Market Share: Scenario A - 2020-2024	411
Table 98 - Self-collection PCR Test Kits Manufacturing Plants Market Size,	
Market Dynamics & Market Share: Scenario B - 2020-2024	412
Table 99 - Ventilators Manufacturing Plants Market Size, Market Dynamics	
& Market Share: Scenario A - 2020-2024	418
Table 100 - Ventilators Manufacturing Plants Market Size, Market	
Dynamics & Market Share: Scenario B - 2020-2024	418
Table 101 - PCR Reagents Manufacturing Plants Market Size, Market	
Dynamics & Market Share: Scenario A - 2020-2024	419
Table 102 - PCR Reagents Manufacturing Plants Market Size, Market	400
Dynamics & Market Share: Scenario B - 2020-2024	420
Table 103 - PCR Systems Manufacturing Plants Market Size, Market	404
Dynamics & Market Share: Scenario A - 2020-2024	421
Table 104 - PCR Systems Manufacturing Plants Market Size, Market	400
Dynamics & Market Share: Scenario B - 2020-2024	422
Table 105 - Nose & Mouth Swabs Manufacturing Plants Market Size,	407
Market Dynamics & Market Share: Scenario A - 2020-2024	1 27
Table 106 - Nose & Mouth Swabs Manufacturing Plants Market Size,	407
Market Dynamics & Market Share: Scenario B - 2020-2024	1 27
Table 107 - COVID-19 Vaccine Manufacturing Plants Market Size, Market	1 20
Dynamics & Market Share: Scenario A - 2020-2024	+20
Table 108 - COVID-19 Vaccine Manufacturing Plants Market Size, Market	420
Dynamics & Market Share: Scenario B - 2020-2024	+29
Table 109 - R&D Equipment & Consumables Market Size, Market	/2N
Dynamics & Market Share: Scenario A - 2020-2024 Table 110 - R&D Equipment & Consumables Market Size, Market	+30
· ·	121
Dynamics & Market Share: Scenario B - 2020-2024 Table 111 - Medical Glass and Other Products & Services Market Size,	+01
Market Dynamics & Market Share: Scenario A - 2020-2024	121
Table 112 - Medical Glass and Other Products & Services Market Size,	7U 1
Market Dynamics & Market Share: Scenario B - 2020-2024	434
191311101 D 9113111100 G 191311001 D113110. D00113110 D - 7 17 17 17 17 T	

List of Figures

Figure 1 - Vaccine Development: Traditional Timeline vs. COVID-19	
Accelerated Timeline	34
Figure 2 - COVID-19 Vaccines Market: Barriers to Entry, Supplier Power,	
Buyer Power and Substitution	54
Figure 3 - Vaccines Market Size [\$M] by Scenario - 2020-2024	
Figure 4 - FDA Testing COVID-19 Treatment	
Figure 5 - Network-Based Drug Repurposing For COVID-19	
Figure 6 - COVID-19 Therapeutic Drug Market: Barriers to Entry, Supplier	
Power, Buyer Power and Substitution	70
Figure 7 - COVID-19 Therapeutic Drugs Market Size [\$M] by Scenario -	
2020-2024	75
Figure 8- Medicines Essential for ICU Care of COVID-19 Patients Are	
Prepped For Shipment in Direct Relief's Warehouse	76
Figure 9 - Other COVID-19 Pharma Industry Products Market: Barriers to	
Entry, Supplier Power, Buyer Power and Substitution	79
Figure 10 - Other Pharma Industry Products Market Size [\$M] by Scenario	
- 2020-2024	81
Figure 11 - Reverse Transcription - Polymerase Chain Reaction (RT-PCR)	
Process	83
Figure 12- PCR Test	84
Figure 13 - PCR Thermal Amplification	85
Figure 14 - Antibody Vs. PCR Testing Methods	87
Figure 15 - RT-PCR Process	89
Figure 16 - COVID-19 PCR Components	91
Figure 17 - PCR Instrumentation & Software Market: Barriers to Entry,	
Supplier Power, Buyer Power and Barriers to Substitution	95
Figure 18 - PCR Instrumentation & Software Market Size [\$M] by Scenario	
- 2020-2024	97
Figure 19 - Robotic COVID-19 PCR Lab Can Process 1000 Patient	
Samples Daily	100
Figure 20 - A Robotic PCR Lab Can Provide Much Needed Testing	
Capacity For Those With Symptoms Consistent With COVID-	
19 Infection	
Figure 21 - Thermo Fisher Robotic Based Lab Automation	101
Figure 22 - Robotic PCR Systems & Software Market: Barriers to Entry,	
Supplier Power, Buyer Power and Substitution	104
Figure 23 - Robotic PCR Systems & Software Market Size [\$M] by	
Scenario - 2020-2024	106
Figure 24 - COVID-19 PCR Kit	107
Figure 25 - PCR Reagents & Consumables Market: Barriers to Entry,	
Supplier Power, Buyer Power and Substitution	110
Figure 26 - PCR Reagents & Consumables Market Size [\$M] by Scenario -	
2020-2024	112
Figure 27 - Nose & Mouth Swabs Collecting Procedure	113

Figure 28 - PCR Sample Using Nose & Mouth Swabs	114
Figure 29 - Nose & Mouth Swabs Market: Barriers to Entry, Supplier	
Power, Buyer Power and Substitution	116
Figure 30 - Nose & Mouth Swabs Market Size [\$M] by Scenario - 2020-	
2024	118
Figure 31 - An Oral Self-Swab Kit	119
Figure 32 - Saliva Test Vials	121
Figure 33 - FDA Approved Saliva Test	122
Figure 34 - Self-collection PCR Test Kits Market Size [\$M] by Scenario -	
2020-2024	
Figure 35 - A Serologic Test Kit	124
Figure 36 - How a Serologic Test Works	
Figure 37 - Antibody Vs. PCR Testing Methods	128
Figure 38 - The Indian Government's Proposed COVID-19 Antibody	
Screening Flowchart	
Figure 39 - Coronavirus Antibody Test Kit	
Figure 40 - Coronavirus IgG Antibody Detection Kit Reading	131
Figure 41 - Serologic Test Kits Market: Barriers to Entry, Supplier Power,	
Buyer Power and Substitution	
Figure 42 - Serologic Test Kits Market Size [\$M] by Scenario - 2020-2024	
Figure 43 - COVID-19 Standoff Thermometry Screening	141
Figure 44 - Body Temperature Measuring & Facial Recognition Access	
Control	
Figure 45 - A Standoff Thermal Camera	
Figure 46 - A Standoff Thermometer Kit	144
Figure 47 - Standoff Thermometry Market Size [\$M] by Scenario - 2020- 2024	146
Figure 48 - A Mobile X-Ray System	148
Figure 49 - A Series of Chest X-Ray Findings of Patient With COVID-19 Demonstrating Clinical Characteristics of Disease	149
Figure 50 - Partial Filling of Air Spaces in The Lungs From Coronavirus	
Figure 51 - X-Ray Procedures Market Size [\$M] by Scenario - 2020-2024	
Figure 52 - The Vatech COVID-19 Dedicated CT System	
Figure 53 - Chest CT images of A COVID-19 Patient. Top Five Days after	
Onset, Bottom 15 Days after Onset	156
Figure 54 - CT Procedures Market Size [\$M] by Scenario - 2020-2024	161
Figure 55 - A Chest Ultrasound Procedure	
Figure 56 - CT and Ultrasound Scans from Two COVID-19 Patients	163
Figure 57 - Ultrasound Procedures Market Size [\$M] by Scenario - 2020-	
2024	168
Figure 58 - Peripheral GGOs with An Increased 18F-FDG Uptake In The	
Right Upper Lung And Left Lower Lung	169
Figure 59 - A PET-CT System	
Figure 60 - Wastewater Testing Market Size [\$M] by Scenario - 2020-2024.	175
Figure 61- A PACS Based Infrastructure Linked to RIS, Viewing Stations	
HIS and Teleradiology Optimizes the Workflow	177

Figure 62 - PACS Distributed Architecture	178
Figure 63 - A Tablet Linked via Teleradiography to a COVID-19 Patient PACS Record	t 181
Figure 64 - PACS & Teleradiology Market Size [\$M] by Scenario - 2020	
2024	
Figure 65 - A PPE Set	185
Figure 66 - Reusable ICU Gowns	
Figure 67 - PPE Gowns Market Size [\$M] by Scenario - 2020-2024	192
Figure 68 -Medical Gloves	193
Figure 69 - Gloves Market Size [\$M] by Scenario - 2020-2024	196
Figure 70 - Face Masks Compared	
Figure 71 - When to Use a Respirator or a Surgical Mask	199
Figure 72 - N95 Respirator Layers	
Figure 73 - Face Masks Market Size [\$M] by Scenario - 2020-2024	
Figure 74 - Face Shields	
Figure 75 - Five Protective Shields Designs	
Figure 76 - Medical Face Shields Market Size [\$M] by Scenario - 2020-	
2024	211
Figure 77 - Eye Protection Market Size [\$M] by Scenario - 2020-2024.	
Figure 78 - PPE Sterilization: Systems & Consumables Market Size [\$1	_
by Scenario - 2020-2024	217
Figure 79 - Hand & Surface Sanitizers Market Size [\$M] by Scenario - 2020-2024	222
Figure 80 - Sterilization Market Size [\$M] by Scenario - 2020-2024	
Figure 81 - Other Personal Protection Gear Market Size [\$M] by Scena	
2020-2024	
Figure 82 - A COVID-19 CT Image	
Figure 83 - Signs of Pneumonia in a Chest X-ray	
Figure 84 - COVID-19 AI, Big Data & Deep Learning Flow Diagram	
Figure 85 - Receiver Operating Characteristic Curves of the Model	
Figure 86 - Example of a COVID-19 Detection Neural Network	
Figure 87 - AI, Big Data & Deep Learning Market Size [\$M] by Scenario	
2020-2024	
Figure 88 - Homecare IT Flowchart	
Figure 89 - Homecare IT Market Size [\$M] by Scenario - 2020-2024	256
Figure 90 - Urban Pandemic Geo-Location System	259
Figure 91 - Countries Enacting Contact Tracing Services to Mitigate the	е
COVID-19 Pandemic by March 2020	260
Figure 92 - Cellphone Displays the Private Kit APP	264
Figure 93 - Pandemic Geo-Location System without Cell Phones	265
Figure 94 - The UK NHS COVID-19 Bluetooth App	266
Figure 95 - Hong Cong, S. Korea & Singapore who Used a COVID-19	
Pandemic Contact Tracing Services Prove the Limited Sp	
of The COVID-19 Vs. Other Countries	
Figure 96 - Face Recognition as Used in China to Augment its Pandem	
Geo-Location System	270

Figure	97 -	Contact Tracing Systems & Services Market Size [\$M] by	
		Scenario - 2020-2024	271
Figure	98 -	E-Health Market Size [\$M] by Scenario - 2020-2024	276
Figure	99 -	Blockchain Technologies Market Size [\$M] by Scenario - 2020-	
		2024	285
Figure	100	- Other ICT Market Size [\$M] by Scenario - 2020-2024	292
Figure	101	- Non-Invasive Ventilator Demonstration	
Figure	102	- Mechanical Ventilator vs. Non-Invasive Ventilator	296
Figure	103	- Helmet-Based Non-Invasive Ventilator	300
Figure	104	- Non-Invasive Ventilators Market: Barriers To Entry, Supplier	
		Power, Buyer Power And Barriers To Substitution	302
Figure	105	- Noninvasive Ventilators Market Size [\$M] by Scenario - 2020-	
		2024	304
Figure	106	- A Mechanical Invasive Ventilator	305
Figure	107	- General Motors / Ventec, VOCSN Multi-function Ventilators	
		Manufactured During April 2020	307
Figure	108	- A Mechanical Ventilator Function	
Figure	109	- System Components Layout & Function	311
Figure	110	- Invasive Mechanical Ventilators Market: Barriers To Entry,	
		Supplier Power, Buyer Power And Barriers To Substitution	315
Figure	111	- Invasive Mechanical Ventilators Market Size [\$M] by Scenario	
		- 2020-2024	317
Figure	112	- Next Generation Ventilators Market: Barriers To Entry,	
		Supplier Power, Buyer Power And Barriers To Substitution	321
Figure	113	- Next Generation Ventilators Market Size [\$M] by Scenario -	
		2020-2024	323
_		- COVID-19 Homecare Elements	325
Figure	115	- Homecare "ICU" Market: Barriers To Entry, Supplier Power,	
		Buyer Power And Barriers To Substitution	330
Figure	116	- Homecare "ICU" (Equipment, Software, Services) Market	
		Size [\$M] by Scenario - 2020-2024	332
•		- A Smiths Group Portable Ventilator	333
_		- An Invasive Portable Ventilator	334
		- Mobile Ventilators Market Size [\$M] by Scenario - 2020-2024	338
Figure	120	- Italian Red Cross Surge Hospital Unit Installed During The	
		Fiera Di San Rocco Pandemic	
		- 52 Bed Surge Hospital	
		- A Russian Tented Surge Hospital	341
Figure	126	- Surge Capacity Hospitals & Surge ICUsMarket Size [\$M] by	
		Scenario - 2020-2024	
		- Kidney Dialysis Market Size [\$M] by Scenario - 2020-2024	
Figure	128	- ECMO System	350
		- ECMO Machine Function	351
Figure	130	- Extracorporeal Oxygenation System Used for a COVID-19	
		Patient	352

Figure	131 - Extracorporeal Membrane Oxygenation Procedures Market	
	Size [\$M] by Scenario - 2020-2024	.357
Figure	132 - Typical COVID-19 ICU Equipment	.358
Figure	133 - Other Intensive Care Modalities Market Size [\$M] by Scenario	
	- 2020-2024	.363
Figure	134 - Ford Manufactures Hospital Gowns with Airbag Material	.364
	•	
	136 - Gowns Manufacturing Plants Market Size [\$M] by Scenario -	
	2020-2024	.368
Figure	137 - Medical gloves coating machine	.370
	138 – Medical PPE Gloves Manufacturing Machine	
Figure	139 – Medical PPE Gloves Manufacturing Line	.371
	140 - Gloves Manufacturing Plants Market Size [\$M] by Scenario -	
	2020-2024	.374
Figure	141 - A Production Line for the Manufacture Of Masks at a Factory	
	in Shanghai	.376
Figure	142 - Automatic Face Mask Making Machine	.378
	143 - N95 Face Mask	.379
Figure	144 - A Garment Production Line Converted To Manufacture Face	
	Masks	.383
Figure	145 – An N95 Respirator Manufacturing Line	.384
Figure	146 - Automatic N95 Respirator Face Mask Forming Production	
	Machine	.385
Figure	147 - Face Masks Manufacturing Plants Market Size [\$M] by	
	Scenario - 2020-2024	.388
Figure	148 - Face Shields Manufacturing Line	.389
Figure	149 - President Trump Visits a New Face Shield Manufacturing Line	.390
Figure	150 - Face Shields Manufacturing Plants Market Size [\$M] by	
	Scenario - 2020-2024	.392
Figure	151 - Test Kits Manufacturing	.393
Figure	152 - Test Kits Assembly Line	.394
Figure	153 – Serologic Test Kits Manufacturing Plants Market Size [\$M] by	
J	Scenario - 2020-2024	.396
Figure	154 - Medical Grade Gown Made Of Melt-Blown Fabric	
_	155 - Melt-Blown PPE Fabric Manufacturing Machine	
_	156 - Production Lines: Three Spun-Bonded Lines, One Melt-Blown	
3	Non-Woven Line and Three Lamination Lines, Producing	
	Melt-Blown Material	.400
Figure	157 - Melt-Blown PPE Fabric Manufacturing Plants Market Size	
9	[\$M] by Scenario - 2020-2024	.404
Figure	158 - Spun-Bond Manufacturing Method	
	159 - Spun-Bond Based Medical PPE	
	160 - Spun Bond Manufacturing Machine	
	161 - Spun-Bond PPE Fabric Manufacturing Plants Market Size	
	[\$M] by Scenario - 2020-2024	.409
Figure	31 - A self-collection PCR sample Kit	

Figure 162 - 3	Self-collection PCR Test Kits Manufacturing Plants Market	
_	Size [\$M] by Scenario - 2020-2024	.412
Figure 163 - '	Ventilators Production Line	.413
Figure 164 -	ICU Ventilators per 100,000 People Over 65	.414
Figure 165 - '	Ventilators Production Final Test Stage	.415
Figure 166 - A	A German Ventilators Production Line	.416
Figure 167 - '	Ventilators Manufacturing Plants Market Size [\$M] by	
J	Scenario - 2020-2024	.418
Figure 168 -	PCR Reagents Manufacturing Plants Market Size [\$M] by	
J	Scenario - 2020-2024	.420
Figure 169 - I	PCR Systems Manufacturing Plants Market Size [\$M] by	
J	Scenario - 2020-2024	.422
Figure 170 - 3	Swabs Manufactures Machine	.423
_		.424
Figure 172 - I	Nose & Mouth Swabs Manufacturing Plants Market Size [\$M]	
J	by Scenario - 2020-2024	. 427
Figure 173 -	COVID-19 Vaccine Manufacturing Plants Market Size [\$M] by	
J	Scenario - 2020-2024	.429
Figure 174 - I	R&D Equipment & Consumables Market Size [\$M] by	
J	Scenario - 2020-2024	. 431
Figure 175 - I	Medical Glass and Other Products & Services Market Size	
S	[\$M] by Scenario - 2020-2024	. 435

COVID-19 Mitigation Products

(PPE, Serologic Test, Contact Tracing System, COVID-19 Drugs, COVID-19 Vaccine, Polymerase Chain Reaction, PCR Test Kits, Blockchain Technologies, Surge Hospitals, Self-collection Swabs, AI, Personal Protection Gear, Teleradiology, Eye Protection, Ultrasound, Dialysis, CT, X-Ray, Medical Glass, Telemedicine, Face Shields, Gowns, Homecare, Gloves, E-Health, Robotic PCR, Antigen Test, Monoclonal Antibody, Face Masks, Therapeutic Drugs, ICU, PACS, Contact Tracing, PPE Sterilization and More)

Market Research, to 2024

Vol.3

Table of Contents

END	USER	MARI	KETS	14
1	Hospi Mitiga 1.1 1.2 1.2. 1.2.	Marke Globa Surge 1	Iarket – 2020-2024	14 14 15
2			s COVID-19 Pandemic Mitigation Market – 2020-	
	2.1	Marke	t Background	
	2.2		I COVID-19 Pandemic Mitigation: Clinical Labs et – 2020-2024	19
	2.2.		COVID-19 Pandemic Mitigation Clinical Labs Market: Scenario A	
	2.2.		COVID-19 Pandemic Mitigation Clinical Labs Market: Scenario B	21
	2.2.	_	Clinical Labs Market: Scenarios Comparison	
3	Clinic 3.1		ID-19 Pandemic Mitigation Market – 2020-2024	
	3.2	Globa	I COVID-19 Pandemic Mitigation: Clinics Market –	
	3.2.		2024COVID-19 Pandemic Mitigation Clinics Market:	24
	3.2.	2	Scenario ACOVID-19 Pandemic Mitigation Clinics Market:	25
			Scenario B	
	3.2.		Clinics Market: Scenarios Comparison	28
4			Medical Services (EMS) COVID-19 Pandemic larket – 2020-2024	29
	4.1		et Background	
	4.2	Globa	I COVID-19 Pandemic Mitigation: Emergency Medical	
	4.2.		ces (EMS) Market – 2020-2024	29
	4.2.	. 1	COVID-19 Pandemic Mitigation Emergency Medical Services (EMS) Market: Scenario A	30
	4.2.	.2	COVID-19 Pandemic Mitigation Emergency Medical	
	4.2.	2	Services (EMS) Market: Scenario B Emergency Medical Services Market: Scenarios	31
	4.2.	.0	Comparison	33

 Market – 2020-2024 5.1 Market Background 5.2 Global COVID-19 Pandemic Mitigation: Homecare & Nursing Homes Market – 2020-2024 5.2.1 COVID-19 Pandemic Mitigation Homecare & Nursing Homes Market: Scenario A. 5.2.2 COVID-19 Pandemic Mitigation Homecare & Nursing Homes Market: Scenario B. 5.2.3 Homecare & Nursing Homes Market: Scenarios Comparison 6 Research Bodies COVID-19 Pandemic Mitigation Market – 2020-2024 6.1 Market Background 6.2 Global COVID-19 Pandemic Mitigation: Research Bodies Market – 2020-2024. 6.2.1 COVID-19 Pandemic Mitigation Research Bodies Market: Scenario A. 6.2.2 COVID-19 Pandemic Mitigation Research Bodies Market: Scenario B. 6.2.3 Research Bodies Market: Scenarios Comparison 	
5.2 Global COVID-19 Pandemic Mitigation: Homecare & Nursing Homes Market – 2020-2024	mecare &
Nursing Homes Market – 2020-2024 5.2.1 COVID-19 Pandemic Mitigation Homecare & Nursing Homes Market: Scenario A. 5.2.2 COVID-19 Pandemic Mitigation Homecare & Nursing Homes Market: Scenario B. 5.2.3 Homecare & Nursing Homes Market: Scenarios Comparison. 6 Research Bodies COVID-19 Pandemic Mitigation Market – 2020-2024 6.1 Market Background. 6.2 Global COVID-19 Pandemic Mitigation: Research Bodies Market – 2020-2024. 6.2.1 COVID-19 Pandemic Mitigation Research Bodies Market: Scenario A. 6.2.2 COVID-19 Pandemic Mitigation Research Bodies Market: Scenario B.	34 necare & Nursing
Nursing Homes Market – 2020-2024 5.2.1 COVID-19 Pandemic Mitigation Homecare & Nursing Homes Market: Scenario A. 5.2.2 COVID-19 Pandemic Mitigation Homecare & Nursing Homes Market: Scenario B. 5.2.3 Homecare & Nursing Homes Market: Scenarios Comparison. 6 Research Bodies COVID-19 Pandemic Mitigation Market – 2020-2024 6.1 Market Background. 6.2 Global COVID-19 Pandemic Mitigation: Research Bodies Market – 2020-2024. 6.2.1 COVID-19 Pandemic Mitigation Research Bodies Market: Scenario A. 6.2.2 COVID-19 Pandemic Mitigation Research Bodies Market: Scenario B.	34 necare & Nursing
5.2.1 COVID-19 Pandemic Mitigation Homecare & Nursing Homes Market: Scenario A	necare & Nursing
Homes Market: Scenario A 5.2.2 COVID-19 Pandemic Mitigation Homecare & Nursing Homes Market: Scenario B 5.2.3 Homecare & Nursing Homes Market: Scenarios Comparison 6 Research Bodies COVID-19 Pandemic Mitigation Market – 2020-2024 6.1 Market Background 6.2 Global COVID-19 Pandemic Mitigation: Research Bodies Market – 2020-2024 6.2.1 COVID-19 Pandemic Mitigation Research Bodies Market: Scenario A 6.2.2 COVID-19 Pandemic Mitigation Research Bodies Market: Scenario B	35 necare & Nursing
5.2.2 COVID-19 Pandemic Mitigation Homecare & Nursing Homes Market: Scenario B. 5.2.3 Homecare & Nursing Homes Market: Scenarios Comparison	necare & Nursing
Homes Market: Scenario B 5.2.3 Homecare & Nursing Homes Market: Scenarios Comparison 6 Research Bodies COVID-19 Pandemic Mitigation Market – 2020-2024 6.1 Market Background 6.2 Global COVID-19 Pandemic Mitigation: Research Bodies Market – 2020-2024 6.2.1 COVID-19 Pandemic Mitigation Research Bodies Market: Scenario A 6.2.2 COVID-19 Pandemic Mitigation Research Bodies Market: Scenario B	
5.2.3 Homecare & Nursing Homes Market: Scenarios Comparison	: Scenarios
Comparison Research Bodies COVID-19 Pandemic Mitigation Market – 2020-2024 6.1 Market Background 6.2 Global COVID-19 Pandemic Mitigation: Research Bodies Market – 2020-2024 6.2.1 COVID-19 Pandemic Mitigation Research Bodies Market: Scenario A 6.2.2 COVID-19 Pandemic Mitigation Research Bodies Market: Scenario B	
6 Research Bodies COVID-19 Pandemic Mitigation Market – 2020-2024 6.1 Market Background 6.2 Global COVID-19 Pandemic Mitigation: Research Bodies Market – 2020-2024 6.2.1 COVID-19 Pandemic Mitigation Research Bodies Market: Scenario A 6.2.2 COVID-19 Pandemic Mitigation Research Bodies Market: Scenario B	Son Market – 39 search Bodies earch Bodies 40 earch Bodies 41
 2020-2024 6.1 Market Background 6.2 Global COVID-19 Pandemic Mitigation: Research Bodies Market – 2020-2024 6.2.1 COVID-19 Pandemic Mitigation Research Bodies Market: Scenario A 6.2.2 COVID-19 Pandemic Mitigation Research Bodies Market: Scenario B 	39 search Bodies39 earch Bodies40 earch Bodies41
 6.1 Market Background	search Bodies39 earch Bodies40 earch Bodies41
 6.1 Market Background	search Bodies39 earch Bodies40 earch Bodies41
 6.2 Global COVID-19 Pandemic Mitigation: Research Bodies Market – 2020-2024	search Bodies 39 earch Bodies 40 earch Bodies 41
Market – 2020-2024	39 earch Bodies40 earch Bodies41
6.2.1 COVID-19 Pandemic Mitigation Research Bodies Market: Scenario A	earch Bodies 40 earch Bodies 41
Market: Scenario A	40 earch Bodies 41
6.2.2 COVID-19 Pandemic Mitigation Research Bodies Market: Scenario B	earch Bodies 41
Market: Scenario B	41
0.2.5 Research Bodies Market. Scenarios Comparison	Companson43
REGIONAL MARKETS	44
7 North America COVID 40 Pendemic Mitiration Market 2000	Montret 2020
7 North America COVID-19 Pandemic Mitigation Market - 2020-	
2024	4.4
7.1 North America End User Markets – 2020-2024	
7.1.1 North America COVID-19 Pandemic Mitigation Market:	02444
Scenario A	02444 Mitigation Market:
7.1.2 North America COVID-19 Pandemic Mitigation Market:	02444 Mitigation Market:44
	02444 Mitigation Market:44 Mitigation Market:
Scenario B	02444 Mitigation Market:44 Mitigation Market:
	02444 Mitigation Market:44 Mitigation Market:46
Scenario B	024
Scenario B	024
Scenario B	024
Scenario B	024 44 Mitigation Market: 44 Mitigation Market: 46
Scenario B	024 44 Mitigation Market: 44 Mitigation Market: 46
Scenario B	024 44 Mitigation Market: 44 Mitigation Market: 46
Scenario B	024 44 Mitigation Market: 44 Mitigation Market: 46
Scenario B	024 44 Mitigation Market: 44 Mitigation Market: 46 48 48 tion Market by 49 Mitigation 49 Mitigation 51 - 2020-2024 53
Scenario B	024 44 Mitigation Market: 44 Mitigation Market: 46 48 48 tion Market by 49 Mitigation 49 Mitigation 51 - 2020-2024 53 53
Scenario B	024 44 Mitigation Market: 44 Mitigation Market: 46 48 48 tion Market by 49 Mitigation 49 Mitigation 51 - 2020-2024 53 53
Scenario B	024 44 Mitigation Market: 44 Mitigation Market: 46 48 48 tion Market by 49 Mitigation 49 Mitigation 51 - 2020-2024 53 ion Market:
Scenario B	024 44 Mitigation Market: 44 Mitigation Market: 46 48 48 tion Market by 49 Mitigation 50 io B 51 - 2020-2024 53 ion Market: 53
Scenario B	024 44 Mitigation Market: 44 Mitigation Market: 46 48 48 tion Market by 49 Mitigation 50 io B 51 - 2020-2024 53 ion Market: 53 ion Market: 53

	8.2 Europ 8.2.1	be COVID-19 Market by Revenue Source – 2020-2024 Europe COVID-19 Pandemic Mitigation Products &	58
	0.2.1	Services Market: Scenario A	58
	8.2.2	Europe COVID-19 Pandemic Mitigation Products &	00
		Services Market: Scenario B	60
9		COVID-19 Pandemic Mitigation Market - 2020-	
		Pacific End User Markets – 2020-2024	61
	9.1.1	Asia-Pacific COVID-19 Pandemic Mitigation Market:	
	0.4.0	Scenario A	61
	9.1.2	Asia-Pacific COVID-19 Pandemic Mitigation Market:	00
	0.4.0	Scenario B	
	9.1.3 9.2 Asia-l	Scenarios Comparison	64
		Pacific COVID-19 Market by Revenue Source – 2020-	65
	9.2.1	Asia-Pacific COVID-19 Pandemic Mitigation Products &	03
	3.2.1	Services Market: Scenario A	65
	9.2.2	Asia-Pacific COVID-19 Pandemic Mitigation Products &	00
	V	Services Market: Scenario B	67
10	MEA 9 Latin	n America COVID-19 Pandemic Mitigation Market	
10	- 2020-2024		60
		& Latin America End User Markets – 2020-2024	
	10.1.1	MEA & Latin America COVID-19 Pandemic Mitigation	00
		Market: Scenario A	69
	10.1.2	MEA & Latin America COVID-19 Pandemic Mitigation	
		Market: Scenario B	71
	10.1.3		73
		& Latin America COVID-19 Market by Revenue	
		ce – 2020-2024	74
	10.2.1	MEA & Latin America COVID-19 Pandemic Mitigation	
	40.00	Products & Services Market: Scenario A	74
	10.2.2	MEA & Latin America COVID-19 Pandemic Mitigation	76
		Products & Services Market: Scenario B	/ 6
NAT	IONAL MAR	KETS	78
11			
		1-19 Pandemic Mitigation Market - 2020-2024et Background	
		COVID-19 Pandemic Mitigation Market Scenarios–	1 0
		-2024	79
40			
12		VID-19 Pandemic Mitigation Market - 2020-2024	
	12.1 Marke	et Backgroundda COVID-19 Pandemic Mitigation Market Scenarios–	ठ T
		2024	82

13.1 13.2	U.K. COVID-19 Pandemic Mitigation Market Scenarios-	
Germ	any COVID-19 Pandemic Mitigation Market - 2020-2024	87
14.1	Market Background	
14.2		88
Franc	ce COVID-19 Pandemic Mitigation Market - 2020-2024	90
15.1		
15.2	O	91
Italy (COVID-19 Pandemic Mitigation Market - 2020-2024	93
16.1		
16.2	Italy COVID-19 Pandemic Mitigation Market Scenarios-	
	2020-2024	94
		96
India	COVID-19 Pandemic Mitigation Market - 2020-2024	98
18.1	Market Background	
18.2	India COVID-19 Pandemic Mitigation Market Scenarios—2020-2024	99
China	a COVID-19 Pandemic Mitigation Market - 2020-2024	101
19.1		
19.2	China COVID-19 Pandemic Mitigation Market Scenarios—2020-2024	102
South		
		104
20.1	Market Background	
20.2		
		107
21.2		108
Rest		
		110
	13.1 13.2 Germ 14.1 14.2 Franc 15.1 15.2 Italy 16.1 16.2 Rest 2020- India 18.1 19.2 China 19.1 19.2 South 20.2 Japan 21.1 21.2 Rest 2020- 21.1 21.2	13.2 U.K. COVID-19 Pandemic Mitigation Market Scenarios—2020-2024. Germany COVID-19 Pandemic Mitigation Market - 2020-2024. 14.1 Market Background. 14.2 Germany COVID-19 Pandemic Mitigation Market Scenarios—2020-2024. France COVID-19 Pandemic Mitigation Market - 2020-2024. 15.1 Market Background. 15.2 France COVID-19 Pandemic Mitigation Market Scenarios—2020-2024. Italy COVID-19 Pandemic Mitigation Market - 2020-2024. 16.1 Market Background. 16.2 Italy COVID-19 Pandemic Mitigation Market Scenarios—2020-2024. Rest of Europe COVID-19 Pandemic Mitigation Market - 2020-2024. India COVID-19 Pandemic Mitigation Market - 2020-2024. 18.1 Market Background. 18.2 India COVID-19 Pandemic Mitigation Market Scenarios—2020-2024. China COVID-19 Pandemic Mitigation Market Scenarios—2020-2024. China COVID-19 Pandemic Mitigation Market Scenarios—2020-2024. South Korea COVID-19 Pandemic Mitigation Market Scenarios—2020-2024. South Korea COVID-19 Pandemic Mitigation Market Scenarios—2020-2024. Japan COVID-19 Pandemic Mitigation Market - 2020-2024. Japan COVID-19 Pandemic Mitigation Market - 2020-2024. Market Background. 20.2 South Korea COVID-19 Pandemic Mitigation Market Scenarios—2020-2024. Japan COVID-19 Pandemic Mitigation Market - 2020-2024. Market Background. 21.2 Japan COVID-19 Pandemic Mitigation Market Scenarios—2020-2024. Rest of Asia-Pacific COVID-19 Pandemic Mitigation Market Scenarios—2020-2024.

List of Tables

Table 1 - Hospitals and Surge Hospitals Market Size by Region [\$M]: Scenario A - 2020-2024	. 15
Table 2 - Hospitals and Surge Hospitals Market Dynamics by Region [%]:	
Scenario A - 2020-2024 Table 3 - Hospitals and Surge Hospitals Market Size by Region [\$M]:	.15
Scenario B - 2020-2024 Table 4 - Hospitals and Surge Hospitals Market Dynamics by Region [%]:	.16
Scenario B - 2020-2024 Table 5 - Clinical Labs Market Size by Region [\$M]: Scenario A - 2020-	.17
2024Table 6 - Clinical Labs Market Dynamics by Region [%]: Scenario A - 2020-	.20
2024 Table 7 - Clinical Labs Market Size by Region [\$M]: Scenario B - 2020-	. 20
2024Table 8 - Clinical Labs Market Dynamics by Region [%]: Scenario B - 2020-	.21
2024	. 22
Table 9 - Clinics Market Size by Region [\$M]: Scenario A - 2020-2024	
Table 11 - Clinics Market Size by Region [\$M]: Scenario B - 2020-2024	
Table 12 - Clinics Market Dynamics by Region [%]: Scenario B - 2020-2024	
Table 13 - Emergency Medical Services (EMS) Market Size by Region [\$M]: Scenario A - 2020-2024	. 30
Table 14 - Emergency Medical Services (EMS) Market Dynamics by Region [%]: Scenario A - 2020-2024	.30
Table 15 - Emergency Medical Services (EMS) Market Size by Region [\$M]: Scenario B - 2020-2024	.31
Table 16 - Emergency Medical Services (EMS) Market Dynamics by Region [%]: Scenario B - 2020-2024	.32
Table 17 - Homecare & Nursing Homes Market Size by Region [\$M]: Scenario A - 2020-2024	.35
Table 18 - Homecare & Nursing Homes Market Dynamics by Region [%]:	
Scenario A - 2020-2024 Table 19 - Homecare & Nursing Homes Market Size by Region [\$M]:	.35
Scenario B - 2020-2024 Table 20 - Homecare & Nursing Homes Market Dynamics by Region [%]:	
Scenario B - 2020-2024 Table 21 - Research Bodies Market Size by Region [\$M]: Scenario A -	
2020-2024Table 22 - Research Bodies Market Dynamics by Region [%]: Scenario A -	
2020-2024Table 23 - Research Bodies Market Size by Region [\$M]: Scenario B -	. 40
2020-2024	.41
Table 24 - Research Bodies Market Dynamics by Region [%]: Scenario B - 2020-2024	.42

Table 25 - North America End User Markets' Size [\$M]: Scenario A - 2020-2024	45
Table 26 - North America End User Markets' Dynamics [%]: Scenario A - 2020-2024	45
Table 27 - North America End User Markets' Size [\$M]: Scenario B - 2020- 2024	
Table 28 - North America End User Markets' Dynamics [%]: Scenario B - 2020-2024	40
Table 29 - North America Market Size by Revenue Source [\$M] Scenario A	
Table 30 - North America Markets Dynamics by Revenue Source [%]: Scenario A - 2020-2024	50
Table 31 - North America Market Size by Revenue Source [\$M] Scenario B - 2020-2024	
Table 32 - North America Markets Dynamics by Revenue Source [%]: Scenario B - 2020-2024	52
Table 33 - Europe End User Markets' Size [\$M]: Scenario A - 2020-2024 Table 34 - Europe End User Markets' Dynamics [%]: Scenario A - 2020-	
2024 Table 35 - Europe End User Markets' Size [\$M]: Scenario B - 2020-2024 Table 36 - Europe End User Markets' Dynamics [%]: Scenario B - 2020-	54 55
2024Table 37 - Europe Market Size by Revenue Source [\$M] Scenario A -	56
2020-2024	58 -
2020-2024	59
Table 40 - Europe Markets Dynamics by Revenue Source [%]: Scenario B	60
2020-2024	- 60
Table 41 - Asia-Pacific End User Markets' Size [\$M]: Scenario A - 2020- 2024	61
Table 42 - Asia-Pacific End User Markets' Dynamics [%]: Scenario A - 2020-2024	62
Table 43 - Asia-Pacific End User Markets' Size [\$M]: Scenario B - 2020-	63
Table 44 - Asia-Pacific End User Markets' Dynamics [%]: Scenario B - 2020-2024	63
	65
Table 46 - Asia-Pacific Markets Dynamics by Revenue Source [%]: Scenario A - 2020-2024	66
Table 47 - Asia-Pacific Market Size by Revenue Source [\$M] Scenario B - 2020-2024	67
Table 48 - Asia-Pacific Markets Dynamics by Revenue Source [%]:	68

Table	49	- MEA & Latin America End User Markets' Size [\$M]: Scenario A - 2020-2024	.70
Table	50	- MEA & Latin America End User Markets' Dynamics [%]:	
		Scenario A - 2020-2024	.70
Table	51	- MEA & Latin America End User Markets' Size [\$M]: Scenario B - 2020-2024	.71
Table	52	- MEA & Latin America End User Markets' Dynamics [%]: Scenario B - 2020-2024	.72
Table	53	- MEA & Latin America Market Size by Revenue Source [\$M] Scenario A - 2020-2024	.74
Table	54	- MEA & Latin America Markets Dynamics by Revenue Source	
Table	55	[%]: Scenario A - 2020-2024 MEA & Latin America Market Size by Revenue Source [\$M]	.75
		Scenario B - 2020-2024	. 76
lable	56	- MEA & Latin America Markets Dynamics by Revenue Source [%]: Scenario B - 2020-2024	.77
Table	57	 USA Market Size, Dynamics and Share: Scenario A - 2020-2024 	.79
Table	58	- USA Market Size, Dynamics and Share: Scenario B - 2020-2024	.80
Table	59	- Canada Market Size, Dynamics and Share: Scenario A - 2020- 2024	. 83
Table	60	- Canada Market Size, Dynamics and Share: Scenario B - 2020- 2024	.83
Table	61		.86
		- U.K. Market Size, Dynamics and Share: Scenario B - 2020-2024	.86
		- Germany Market Size, Dynamics and Share: Scenario A - 2020- 2024	.89
Table	64	- Germany Market Size, Dynamics and Share: Scenario B - 2020- 2024	.89
Table	65	- France Market Size, Dynamics and Share: Scenario A - 2020-	. 92
Tabla	66	2024	.92
rabie	00	- France Market Size, Dynamics and Share: Scenario B - 2020-	00
T-1-1-	^ -	2024	.92
		- Italy Market Size, Dynamics and Share: Scenario A - 2020-2024	
		- Italy Market Size, Dynamics and Share: Scenario B - 2020-2024	. 95
		- Rest of Europe Market Size, Dynamics and Share: Scenario A - 2020-2024	. 96
Table	70	- Rest of Europe Market Size, Dynamics and Share: Scenario B - 2020-2024	. 96
Table	71	- India Market Size, Dynamics and Share: Scenario A - 2020- 2024	100
Table	72	- India Market Size, Dynamics and Share: Scenario B - 2020- 2024	
Tablo	72	- China Market Size, Dynamics and Share: Scenario A - 2020-	100
		2024	103
Table	74	- China Market Size, Dynamics and Share: Scenario B - 2020- 2024	103

Table 75 - South Korea Market Size, Dynamics and Share: Scenario A -	405
2020-2024	.105
Table 76 - South Korea Market Size, Dynamics and Share: Scenario B -	
2020-2024	.106
Table 77 - Japan Market Size, Dynamics and Share: Scenario A - 2020-	
2024	.109
Table 78 - Japan Market Size, Dynamics and Share: Scenario B - 2020-	
2024	.109
Table 79 - Rest of Asia-Pacific Market Size, Dynamics and Share: Scenario	
A - 2020-2024	.110
Table 80 - Rest of Asia-Pacific Market Size, Dynamics and Share: Scenario	
	.110
Table 81 - ROW Market Size, Dynamics and Share: Scenario A - 2020-	
2024	.112
Table 82 - ROW Market Size, Dynamics and Share: Scenario B - 2020-	
2024	.112
	· · · -

List of Figures

Figure 1 - Hospitals and Surge Hospitals Market Size by Region [\$M]: Scenario A - 2020-2024	. 15
Figure 2 - Hospitals and Surge Hospitals Market Shares by Region [%]: Scenario A - 2020-2024	.16
Figure 3 - Hospitals and Surge Hospitals Market Size by Region [\$M]: Scenario B - 2020-2024	.16
Figure 4 - Hospitals and Surge Hospitals Market Shares by Region [%]: Scenario B - 2020-2024	. 17
Figure 5 - Hospitals and Surge Hospitals Markets Size [\$M]: Scenarios A and B - 2020-2024	.18
Figure 6 - Clinical Labs Market Size by Region [\$M]: Scenario A - 2020- 2024	.20
Figure 7 - Clinical Labs Market Shares by Region [%]: Scenario A - 2020-2024	.21
Figure 8 - Clinical Labs Market Size by Region [\$M]: Scenario B - 2020- 2024	.21
Figure 9 - Clinical Labs Market Shares by Region [%]: Scenario B - 2020-2024	.22
	.23
	.25
Figure 12 - Clinics Market Shares by Region [%]: Scenario A - 2020-2024	
Figure 13 - Clinics Market Size by Region [\$M]: Scenario B - 2020-2024	
Figure 14 - Clinics Market Shares by Region [%]: Scenario B - 2020-2024	
Figure 15 - Clinics Market Size [\$M]: Scenarios A and B - 2020-2024	
Figure 16 - Emergency Medical Services (EMS) Market Size by Region	. 20
	.30
[\$M]: Scenario A - 2020-2024	. 30
Figure 17 - Emergency Medical Services (EMS) Market Shares by Region	21
[%]: Scenario A - 2020-2024	.31
Figure 18 - Emergency Medical Services (EMS) Market Size by Region [\$M]: Scenario B - 2020-2024	.32
	. 32
Figure 19 - Emergency Medical Services (EMS) Market Shares by Region [%]: Scenario B - 2020-2024	.32
	. 32
Figure 20 - Emergency Medical Services Market Size [\$M]: Scenarios A and B - 2020-2024	22
	. აა
Figure 21 - Homecare & Nursing Homes Market Size by Region [\$M]: Scenario A - 2020-2024	25
	. 33
Figure 22 - Homecare & Nursing Homes Market Shares by Region [%]:	26
Scenario A - 2020-2024	. 30
Figure 23 - Homecare & Nursing Homes Market Size by Region [\$M]:	27
Scenario B - 2020-2024	.3/
Figure 24 - Homecare & Nursing Homes Market Shares by Region [%]:	^-
Scenario B - 2020-2024	.3/
Figure 25 - Homecare & Nursing Homes Market Size [\$M]: Scenarios A	00
and B - 2020-2024	. პ8

Figure	26 -	Research Bodies Market Size by Region [\$M]: Scenario A - 2020-2024	. 40
Figure	27 -	Research Bodies Market Shares by Region [%]: Scenario A - 2020-2024	.41
Figure	28 -	Research Bodies Market Size by Region [\$M]: Scenario B -	. 4 1 . 42
Figure	29 -	Research Bodies Market Shares by Region [%]: Scenario B - 2020-2024	. 42 . 42
Figure	30 -	Research Bodies Market Size [\$M]: Scenarios A and B - 2020- 2024	. 42 . 43
Figure	31 -	North America End User Markets' Size [\$M]: Scenario A - 2020- 2024	. 43 . 45
Figure	32 -	North America End User Markets' Shares [%]: Scenario A - 2020-2024	. 4 3
Figure	33 -	North America End User Markets' Size [\$M]: Scenario B - 2020- 2024	. 4 0
Figure	34 -	North America End User Markets' Shares [%]: Scenario B - 2020-2024	<i>1</i> . 47
Figure	35 -	North America COVID-19 Pandemic Mitigation Market [\$]: Scenarios A and B	. 47 . 48
Figure	36 -	North America Market Shares by Revenue Source [%]: Scenario A - 2020-2024	. 50
Figure	37 -	North America Market Shares by Revenue Source [%]: Scenario B - 2020-2024	. 52
Figure	38 -	Europe End User Markets' Size [\$M]: Scenario A - 2020-2024	. 52 . 54
_		· Europe End User Markets' Shares [%]: Scenario A - 2020-2024 · Europe End User Markets' Shares [%]: Scenario A - 2020-2024	. 54 . 55
_		Europe End User Markets' Size [\$M]: Scenario B - 2020-2024	. 56 . 56
		· Europe End User Markets' Shares [%]: Scenario Β - 2020-2024	. 50 . 57
_		Europe COVID-19 Pandemic Mitigation Market [\$]: Scenarios A	.57
i igui e	42 -	and B	.57
Figure	43 -	Europe Market Shares by Revenue Source [%]: Scenario A - 2020-2024.	. 57
Figure	44 -	Europe Market Shares by Revenue Source [%]: Scenario B - 2020-2024	
Figure	45 -	· Asia-Pacific End User Markets' Size [\$M]: Scenario A - 2020- 2024	
Figure	46 -	Asia-Pacific End User Markets' Shares [%]: Scenario A - 2020- 2024	
Figure	47 -	· Asia-Pacific End User Markets' Size [\$M]: Scenario B - 2020- 2024	. 63
Figure	48 -	Asia-Pacific End User Markets' Shares [%]: Scenario B - 2020- 2024	
Figure	49 -	- Asia-Pacific COVID-19 Pandemic Mitigation Market [\$]: Scenarios A and B	
Figure	50 -	Asia-Pacific Market Shares by Revenue Source [%]: Scenario A	.04 66

Figure 51 - Asia-Pacific Market Shares by Revenue Source [%]: Scenario B	00
- 2020-2024Figure 52 - MEA & Latin America End User Markets' Size [\$M]: Scenario A	68
	70
Figure 53 - MEA & Latin America End User Markets' Shares [%]: Scenario	
A - 2020-2024	71
Figure 54 - MEA & Latin America End User Markets' Size [\$M]: Scenario B	
- 2020-2024	72
Figure 55 - MEA & Latin America End User Markets' Shares [%]: Scenario	72
B - 2020-2024Figure 56 – MEA & Latin America COVID-19 Pandemic Mitigation Market	12
	73
Figure 57 - MEA & Latin America Market Shares by Revenue Source [%]:	7 0
	75
Figure 58 - MEA & Latin America Market Shares by Revenue Source [%]:	
Scenario B - 2020-2024	77
Figure 59 – U.S. Confirmed Cases per Million Residents by State as of	
May 26, 2020	
Figure 60 - USA Market Size [\$M] by Scenario - 2020-2024	80
Figure 61 – Canada Confirmed Cases per Million Residents by	
Province/Territory as of May 26, 2020	
Figure 62 - Canada Market Size [\$M] by Scenario - 2020-2024	83
Figure 63 – U.K. Confirmed Cases per Ten Thousand Residents as of May	05
26, 2020Figure 64 - U.K. Market Size [\$M] by Scenario - 2020-2024	
Figure 65 – Germany Confirmed Cases per 10,000 Inhabitants by District	
Figure 66 - Germany Market Size [\$M] by Scenario - 2020-2024	
Figure 67 – France Deaths per Million Residents by Department	
Figure 68 - France Market Size [\$M] by Scenario - 2020-2024	
Figure 69 – Italy Confirmed Cases per Million Residents by Province (as of	
25 May 2020)	94
Figure 70 - Italy Market Size [\$M] by Scenario - 2020-2024	
Figure 71 - Rest of Europe Market Size [\$M] by Scenario - 2020-2024	
Figure 72 - Map of the Pandemic in India (as of 28 May 2020)	
Figure 73 - India Market Size [\$M] by Scenario - 2020-2024	100
Figure 74 - Confirmed COVID-19 Cases in Mainland China per Million	400
Inhabitants by Province as of 13 April 2020	102
Figure 75 - China Market Size [\$M] by Scenario - 2020-2024	103
Figure 76 - Confirmed Cases per Million Residents by Province or City in South Korea	105
Figure 77 - South Korea Market Size [\$M] by Scenario - 2020-2024	
Figure 78 – Japan Confirmed Cases per Million Residents by Prefecture	
Figure 79 - Japan Market Size [\$M] by Scenario - 2020-2024	
Figure 80 - Rest of Asia-Pacific Market Size [\$M] by Scenario - 2020-2024	
Figure 81 - ROW Market Size [\$M] by Scenario - 2020-2024	113

COVID-19 Mitigation Products

(PPE, Serologic Test, Contact Tracing System, COVID-19 Drugs, COVID-19 Vaccine, Polymerase Chain Reaction, PCR Test Kits, Blockchain Technologies, Surge Hospitals, Self-collection Swabs, AI, Personal Protection Gear, Teleradiology, Eye Protection, Ultrasound, Dialysis, CT, X-Ray, Medical Glass, Telemedicine, Face Shields, Gowns, Homecare, Gloves, E-Health, Robotic PCR, Antigen Test, Monoclonal Antibody, Face Masks, Therapeutic Drugs, ICU, PACS, Contact Tracing, PPE Sterilization and More)

Market Research, to 2024 Vol.4

Table of Contents

MAJ	IOR VE	NDORS	8
1	Vendo 1.1 1.2 1.3	Company Profile	8 8
2	Vendo 2.1 2.2 2.3	Company Profile	11 11
3	Vende 3.1 3.2 3.3	Company Profile	13 13
4	Vende 4.1 4.2 4.3	Company Profile	15 15
5	Vendo 5.1 5.2 5.3	Company Profile	17 17
6	Vendo 6.1 6.2 6.3	Company Profile	18 18
7	Vendo 7.1 7.2 7.3	Company Profile	19 19
8	Vendo 8.1 8.2 8.3	Company Profile	21 21
9	Vendo 9.1 9.2 9.3	Company Profile	23 24
10	Vendo 10.1	Company Profile	

	10.2	2017- 2019 Financials		26
	10.3	COVID-19 Mitigation Activities &	Products	26
11	Vend	or 11		27
	11.1	Company Profile		27
	11.2	2017- 2019 Financials		
	11.3	COVID-19 Mitigation Activities &	Products	28
12	Vend	or 12		29
	12.1	Company Profile		29
	12.2	2017- 2019 Financials		
	12.3	COVID-19 Mitigation Activities &	Products	30
13	Vend	or 13		31
	13.1	Company Profile		
	13.2	2017- 2019 Financials		
	13.3	COVID-19 Mitigation Activities &	Products	32
14	Vend	or 14		33
	14.1	Company Profile		
	14.2	2017- 2019 Financials		
	14.3	COVID-19 Mitigation Activities &	Products	34
15	Vend	or 15		35
		Company Profile		
	15.2			
	15.3	COVID-19 Mitigation Activities &		
16	Vend	or 16		37
. •		Company Profile		
	16.2	2017- 2019 Financials		
	16.3	COVID-19 Mitigation Activities &		
17	Vend	or 17		40
• •	17.1	Company Profile		
	17.2	2017- 2019 Financials		
	17.3	COVID-19 Mitigation Activities &		
18		or 18		
10	18.1	Company Profile		42
	18.2			
	_	COVID-19 Mitigation Activities &		
19		or 19		
19	19.1	Company Profile		
	_	2017- 2019 Financials		
	19.3	COVID-19 Mitigation Activities &		
20		or 20		
20	20.1	Company Profile		
		2016- 2018 Financials		
		COVID-19 Mitigation Activities &		
	_0.0	COVID TO MINIGUNOTI / TONVINOS C		

21		or 21 Company Profile 2017- 2019 Financials COVID-19 Mitigation Activities & Products	.47 .47
22		or 22 Company Profile 2017- 2019 Financials. COVID-19 Mitigation Activities & Products	. <mark>49</mark> . 49 . 49
23	Vende 23.1 23.2 23.3	or 23 Company Profile 2017- 2019 Financials COVID-19 Mitigation Activities & Products	.51 .51
24	24.1 24.2	or 24 Company Profile 2017- 2019 Financials COVID-19 Mitigation Activities & Products	.53 .53
25	Vende 25.1 25.2 25.3	or 25 Company Profile	. 55 . 55
26	Vende 26.1 26.2 26.3	or 26 Company Profile 2017- 2019 Financials COVID-19 Mitigation Activities & Products	.57 .57
27		or 27 Company Profile 2017- 2019 Financials COVID-19 Mitigation Activities & Products	.59 .60
28	28.1 28.2	or 28 Company Profile	61 62
29	29.1 29.2	or 29 Company Profile	.64 .64
30	30.1 30.2	or 30 Company Profile 2017- 2019 Financials COVID-19 Mitigation Activities & Products	.66 .66
31		or 31 Company Profile	

31.3	COVID-19 Mitigation Activities & Products	67
Vend	lor 32	68
32.1		
32.2		
32.3	COVID-19 Mitigation Activities & Products	69
Vend	lor 33	69
33.2	2017- 2019 Financials	70
33.3	COVID-19 Mitigation Activities & Products	71
Vend	lor 34	71
34.1		
34.2		
34.3	COVID-19 Mitigation Activities & Products	73
Vend	lor 35	74
35.1		
35.2		
35.3	COVID-19 Mitigation Activities & Products	75
Vend	lor 36	75
36.1		
36.2	• •	
36.3	COVID-19 Mitigation Activities & Products	77
Vend	lor 37	78
37.1		
37.2		
37.3	COVID-19 Mitigation Activities & Products	79
	31.3 Vend 32.1 32.2 32.3 Vend 33.1 33.2 33.3 Vend 34.1 34.2 34.3 Vend 35.1 35.2 35.3 Vend 36.1 36.2 36.3 Vend 37.1 37.2	Vendor 32 32.1 Company Profile 32.2 2017- 2019 Financials 32.3 COVID-19 Mitigation Activities & Products Vendor 33 33.1 Company Profile 33.2 2017- 2019 Financials 33.3 COVID-19 Mitigation Activities & Products Vendor 34 34.1 Company Profile 34.2 2008- 2010 Financials 34.3 COVID-19 Mitigation Activities & Products Vendor 35 35.1 Company Profile 35.2 2017- 2019 Financials 35.3 COVID-19 Mitigation Activities & Products Vendor 36 36.1 Company Profile 36.2 2017- 2019 Financials 36.3 COVID-19 Mitigation Activities & Products Vendor 36 36.1 Company Profile 36.2 2017- 2019 Financials 36.3 COVID-19 Mitigation Activities & Products Vendor 37 37.1 Company Profile 37.2 2013- 2015 Financials

COVID-19 Mitigation Products

(PPE, Serologic Test, Contact Tracing System, COVID-19 Drugs, COVID-19 Vaccine, Polymerase Chain Reaction, PCR Test Kits, Blockchain Technologies, Surge Hospitals, Self-collection Swabs, AI, Personal Protection Gear, Teleradiology, Eye Protection, Ultrasound, Dialysis, CT, X-Ray, Medical Glass, Telemedicine, Face Shields, Gowns, Homecare, Gloves, E-Health, Robotic PCR, Antigen Test, Monoclonal Antibody, Face Masks, Therapeutic Drugs, ICU, PACS, Contact Tracing, PPE Sterilization and More)

Market Research, to 2024 Vol.5

Table of Contents

APP	ENDICES		10
1	Flu and (x 1: Differences & Similarities Between Common Coronavirus	10
2	(PPE) for 2.1 Int 2.2 Co 2.3 Fir	x 2: Coronavirus Personal Protective Equipment Healthcare Personnel roduction Inclusions Indings Summary Inckground Inckground Inclusion of the Condition Inckground	12 15 19 19 20 23
3	Eye Proto 3.1 Int	,	26 27 27
4	4.1 Pu 4.2 Co 4.3 Co 4.4 Cri	x 4: CDC Strategies for Optimizing the Supply of Gowns rpose noventional Capacity Strategies ontingency Capacity Strategies isis Capacity Strategies tended Use of Isolation Gowns Re-use of Cloth Isolation Gowns Prioritize Gowns When No Gowns Are Available	29 31 32 33 33
5	Facemas5.1 Pu5.2 Co5.3 Co	x 5: CDC Strategy for Optimizing the Supply of sks rpose	35 36 36

6		endix 6: CDC Strategies for Optimizing the Supply of Respirators	40			
7	Appe	ndix 7: CDC Adult Vaccine Price List	43			
	7.1	CDC Vaccine 2020-2021 Price List				
	7.2	CDC Influenza Vaccine 2020-2021 Price List	44			
8	Appe	endix 8: The CDC COVID-19 Bio-Safety Guidelines	46			
	8.1	The CDC Safety Practices for Critical Infrastructure				
		Workers Exposed to a Person with Suspected or Confirmed				
	0.0	COVID-19				
	8.2	Use of Cloth Face Coverings				
	8.3	The Emergency Medical Services Guidance				
	8.4	Recommendations for 911 PSAPs				
	8.4					
	8.5					
	8.5					
	8.6 8.7	Recommended Personal Protective Equipment				
	8.8	Precautions for Aerosol-Generating Procedures EMS Transport of a PUI or Patient with Confirmed COVID-	51			
	0.0	19 to a Healthcare Facility	E 1			
	8.9	Documentation Of Patient Care				
	8.10	Cleaning EMS Transport Vehicles after Transporting a PUI	52			
	0.10	or Patient with Confirmed COVID-19	53			
	8.11	Measures by EMS Clinicians After Caring for a PUI or				
	0.11	Patient with Confirmed COVID-19	54			
	8.12	EMS Employer Responsibilities				
_						
9		endix 9: The 2020 Global Desperation to Protect Medical	=-			
	Work	ers	56			
10	Appe	endix 10: Disinfection Procedures for COVID-19	59			
	10.1	Disinfection for Floor and Walls				
	10.2	Disinfection of Object Surfaces	59			
	10.3	Air Disinfection	59			
	10.4	Disposal of Fecal Matter and Sewage				
	10.5	Disposal Procedures for Spills of COVID-19 Patient				
		Blood/Fluids	60			
11	Appendix 11: Breakdown of the COVID-19 USA Medical					
•	Services Stimulus April 2020					
	11.1	·				
		March 2020	61			
	11 2	For Advance Construction, Manufacture, And Purchase Of	0 1			
		Vaccines And Therapeutic Delivery	61			
	11.3	Telehealth, Poison Control Centers, And The Ryan White				
		HIV/AIDS Program	61			
	11.4	National Institutes of Health				

	11.5		tance Abuse and Mental Health Services	60		
	11.6	Admii	nistrationnistration for Children and Families	b∠ 63		
	_		ans Health Administration			
12	Appe	ndix 1	2: European Preparedness Against Emerging			
_				64		
13	Appe	ndix 1	3: Development and Regulation by the CDC and			
	FDA Diagnostic Testing for COVID-19					
			luction			
			nostic Tests			
	_	.1.1	IVD Tests			
		.1.2	LDT Tests			
		.1.3	How are IVD Tests Regulated?			
		.1.4 .1.5	How are LDTs Regulated?	70		
	13.	.1.5	Regulation?	70		
	13	.1.6	How are IVDs Regulated by the FDA During an	10		
	10.	. 1.0	Emergency Such as the Outbreak of COVID-19?	71		
	13.	.1.7	How Does the Emergency Use Authority Apply to LDTs			
			if They Are Generally Exempted from Premarket			
			Requirements?	71		
	13.	.1.8	How Does the CDC's COVID-19 Diagnostic Test Work?.	72		
	13.	.1.9	What Type of IVD is the CDC's Test and Who May			
			Carry it Out?	73		
	13.	.1.10	What Is the Role of the Commercial Manufacturer IDT			
			in the Development and Distribution of the CDC's Test	7.4		
	12	.1.11	Kit? What Quality Problems Did the CDC's Test Experience	/ 4		
	13.	. 1 . 1 1	on Rollout to the State and Local Public Health			
			Laboratories?	7/		
	13	1.12	What Steps did the FDA Take to Expand Testing	/ ¬		
	10.	2	Capacity in Response to the Problems with the CDC's			
			Test?	75		
14	Anno	ndiv 1	4: The U.S. Defense Production Act: Example			
14			ID-19 Supply Chain Stabilization	76		
				7 0		
15			5: The Global Research Collaboration for			
			Disease Preparedness (GLOPID-R)			
16	Appe	ndix 1	6: Comparing Clinical COVID-19 Data by Nation	80		
	16.1 Introduction					
	16.2		ting Deaths Protocols			
	16.3		nal Death Rates			
			nal Political Factors			
	16.5 16.6		nal Testing Protocolslusions: Comparisons are Difficult			
	ס.טו	COLIC	เนอเบเเอ. บบเท่นสาเอบเเอ สโซ มีเทีเบ็นใน	04		

17	Appe	ndix 17: Home Healthcare IT	85				
	17.1	Introduction	85				
	17.2	Online Bots					
	17.3	Home Telehealth					
	17.4	Telemedicine Billing					
	17.5	Commercial Insurance	88				
18	Appe	ndix 18: The Difference between PCR and Antibody					
	Tests	S	90				
19	Appendix 19: COVID-19 Pandemic Global Economic Effects-						
		2021	91				
	19.1	Introduction	91				
	19.2	Economic Effects	93				
	19.3	USA					
	19.4	Europe					
	19.5	The UK	_				
	19.6	Japan					
	19.7	China					
	19.8 19.9	The IMF The World Bank					
		Emerging Markets					
		Other Sectors					
00							
20	20.1	ndix 20: COVID-19 Tests					
	20.1	COVID-19 Tests Sensitivity and Specificity RT-PCR tests					
	20.2	Antibody Tests					
	20.4	Other Diagnostic Options					
	20.5	Procurement of Test Kits and Consumables					
	20.6	Annex A: Test Kit Options from WHO Diagnostics					
		Consortium	109				
21	Anne	Appendix 21: Rapid Communication on the Role of the					
	GeneXpert® Platform for Rapid Molecular Testing for SARS-						
	CoV-2 in the WHO European Region						
22		ndix 22: Abbreviations					
23		ndix 23: Glossary					
24	Appe	ndix 24: Bibliography	136				
25	Research Methodology						
23	25.1 Scope						
	25.2 Research Methodology						
26		aimer & Copyright					
4 U							

List of Tables

Table 1 - Summary of Findings for the Main Comparison. PPE-Types: One	
Type of PPE versus Another – PAPR versus E-RCP Attire	15
Table 2 - Summary of Findings 2. PPE Types: One Type of PPE versus	
Another – Three Types of PPE Attire	15
Table 3 - Summary of Findings 3. PPE Types: One Type of PPE versus	
Another – Gowns versus Aprons	16
Table 4 - Summary of Findings 5. PPE Types: One Type of PPE versus	
Another - Sealed Suit Compared To Traditional Suit	16
Table 5 - Summary of Findings 6. Procedures: Doffing With Double Gloves	
versus Doffing With Single Gloves	17
Table 6 - Summary of Findings 8. Procedures: Mask Tabs versus No Mask	
Tabs	17
Table 7 - Summary of Findings 9. Procedures: Doffing According To CDC	
Method versus Individual Doffing	17
Table 8 - Summary of Findings 10. Procedures: Doffing With Hypochlorite	
versus Doffing With Alcohol-Based Glove Sanitizer	18
Table 9 - Summary of Findings 11. Procedures: Doffing With Chlorine	
Spray versus Doffing Without Spray	18
Table 10 - Summary of Findings 12. Teaching: Video-Based Learning	
versus Traditional Lecture	
Table 11 - CDC Vaccine 2020-2021 Price List	
Table 12 - CDC Influenza Vaccine 2020-2021 Price List	44
Table 13 – The OECD Global Economic Outlook Forecast. 2019-2021	92

List of Figures

41
56
73
76
77
81
90
00
01